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Smoking is a major cause of morbidity and mortality, and is a costly problem 
worldwide. The epidemiological and economic burden of smoking has been well studied 
both internationally and locally. However, more work needs to be done to evaluate its 
humanistic burden which to the best of our knowledge, has never been evaluated in 
Singapore. To cope with the burden, we think that the workplace is ideal as a setting to 
promote smoking cessation. However, the uptake rate of workplace-based smoking 
cessation programs (WPSCP) in Singapore is dismal according to communications by the 
local Health Promotion Board.  
Therefore, in the first part of this thesis, we evaluated the association of smoking 
status with health-related quality of life (HRQoL) in a multiethnic Singapore population. 
Results from the cross-sectional survey of 3006 participants revealed that smoking was 
associated with a trend of lower HRQoL, although results did not reach statistical 
significance for all instruments. When stratified by gender, female regular smokers 
reported significantly lower HUI3 utility scores, whereas male ex-smokers reported 
statistically lower SF-36v2 MCS and HUI3 utility scores as compared to non-smokers. 
This suggest that besides emphasizing the adverse effects of smoking and lower HRQoL 
amongst smokers, public health initiatives should also incorporate strategies to improve 
the HRQoL of ex-smokers to prevent their relapse. 
In the second part of this thesis, we attempted to understand the issues 
surrounding low uptake rate of WPSCP and to provide suggestions for improvement. 
Firstly, we interviewed 40 companies to evaluate the employers’ perceived barriers, 
x 
 
perceived benefits and resource needs in implementing WPSCP. With a better 
understanding of employers’ motivations and challenges, we provided specific 
suggestions for improving existing WPSCP. We further evaluated the types of smoking 
cessation interventions likely to be implemented by the companies and found meaningful 
differences in the perceived effectiveness, feasibility and willingness to implement 
between company types and sizes. Finally, a cost-benefit analysis was carried out to 
support a business case for WPSCP. We showed that although it cost the company S$700 
(US$ PPP 648) to carry out WPSCP in the first year (in a hypothetical company with 100 
smoking employees), the program can potentially generate savings to the company if it is 
continuously carried out for more than a year or if co-payment is introduced.  
We believe that this thesis has contributed new knowledge that can guide decision 
makers and future research in reducing the humanistic burden of smoking and improving 
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Introduction                                                                                                           
Smoking is widely known to be the major cause of preventable mortality and 
morbidity. In this chapter, the prevalence of smoking will be discussed, with a focus on 
the changes over the years in Singapore. The burden of the smoking epidemic will also be 
discussed in terms of its impact on reduced health outcomes, increased social cost as well 
as reduced quality of life. An overview of the strategies employed to combat this 
epidemic will be provided, as well as smoking control within Singapore that provides an 
insight into Singapore’s commitment to make non-smoking the cultural norm. Through 
this overview, research gaps were identified and developed into specific research 
questions that will be addressed by studies in subsequent chapters of the thesis.  
 
1.1 The smoking epidemic  
Nearly 20% of the world’s adult population, including an estimate of 800 million 
men and 200 million women smoke cigarettes [1]. Consumption was traditionally highest 
in high-income countries, but due to targeted marketing, increased social acceptability, 
economic development and population increases, there is a rise in cigarette consumption 
in low- and middle-income countries. Between 1990 and 2009, cigarette consumption in   
Western Europe dropped by 26%, but increased in the Middle East and Africa by 57%. 




1.1.1 A focus on Singapore  
Singapore, a modern island city state in Southeast Asia, has a population of 5.399 
million people as of 2013, of which 3.844 million (71%) are Singapore residents, 
consisting of citizens and permanent residents. Ethnic Chinese formed the majority at 
74.2% of the resident population, followed by ethnic Malays at 13.3%, ethnic Indians at 
9.1% and others at 3.4% [3].  
The prevalence of daily smoking among adult Singapore residents has shown a 
decreasing trend over the years [4-9], amidst efforts by the Singapore government to curb 
this problem since the 1970s (Figure 1-1).  
Figure 1-1 Crude prevalence of daily smoking (%) among Singapore adult residents, 
1977 to 2010 
 
Source: Emmanuel 1988, 1997; NHS 1998, 2004, 2010; NHSS 2007  
































Figure 1-2). Although female smoking prevalence has always been low, it is 
worth noting that there is an increasing trend of young females aged 18-29 smoking since 
1998, and also a sudden increase in females aged 40-49 smoking based on the latest 
National Health Survey (NHS) 2010 (Table 1-1). 
The Students' Health Surveys carried out in Secondary 1-4 students in Singapore 
schools showed that the prevalence of smoking among minors aged 13 to 16 years 
declined from 9% in 2006 to 6% in 2012 [10].  The median age of smoking initiation for 
this group of student were 12 years old [10]. Studies have shown that smoking 
experimentation and initiation usually takes place during adolescence [11, 12]. The 
United States (US) Surgeon General’s report highlighted that young adults are unlikely to 
pick up smoking if they do not do so by the age of 25 years [12]. By preventing teenagers 
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from lighting up, this will help reduce the prevalence of them smoking in their adult years 












Figure 1-2 Crude prevalence of daily smoking (%) among Singapore adult residents, by 
gender, 1977 to 2010 
 
Source: Emmanuel 1988, 1997; NHS 1998, 2004, 2010; NHSS 2007 



























1998 2004 2007 2010 1998 2004 2007 2010 1998 2004 2007 2010 
18-29 26.2 18.2 25.4 25.3 5.2 6.6 9.1 7.3 15.7 12.3 17.2 16.3 
30-39 25.1 22.7 21.8 29.3 2.4 3.7 4.2 4.3 13.8 13.0 12.8 16.4 
40-49 31.7 24.7 24.6 24.2 1.1 2.2 1.3 4.8 16.7 13.5 13.0 14.5 
50-59 24.9 23.1 24.2 21.2 4.2 1.8 0.7 1.5 14.5 12.5 12.5 11.4 
60-69 26.5 17.6 20.4 22.1 4.3 2.0 2.1 1.2 15.1 9.6 11.0 11.4 
18-69 27.1 21.8 23.7 24.7 3.2 3.5 3.7 4.2 15.2 12.6 13.6 14.3 
Source: NHS 1998, 2004, 2010; NHSS 2007 
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In terms of ethnicity, Malays have consistently recorded the highest prevalence of 
daily smoking over the years (Figure 1-3). This was despite targeted efforts by the 
government to reduce smoking in this ethnic group.  
Figure 1-3 Smoking prevalence (crude rates) among Singapore adult residents by 
ethnicity, 1977 to 2010 
 
Source: Emmanuel 1988, 1997; NHS 1998, 2004, 2010; NHSS 2007 
 
1.2 The burden of smoking 
1.2.1 Health consequences of smoking 
Smoking has been the subject of extensive research on human health risk. The 
“British Doctors Study”, a 50-year prospective cohort study, provided powerful 
epidemiologic evidence comparing the overall survival of smokers and non-smokers over 
time and convincing statistical proof that showed remarkable difference in mortality rates 































well accepted as a main cause of morbidity and mortality. Up to half of all lifetime 
smokers will ultimately die of a disease caused by smoking [2].  
Around the world, tobacco kills nearly 6 million people each year, out of which, 
more than 5 million are the result of direct tobacco use [15] while more than 600 000 
deaths are of non-smokers exposed to second-hand smoke [16]. By 2030, the numbers are 
projected to increase to 8 million deaths annually unless urgent actions are taken [2].  
A wide range of diseases and conditions are caused or can be attributed to 
smoking [12, 17]. Smoking affects almost every organ in the body, causing much harm 
mainly to the heart and lungs. It is a major risk factor for strokes, coronary heart and 
other circulatory diseases, chronic obstructive pulmonary disease and other respiratory 
diseases, and is also associated with many types of cancer, particularly lung cancer, 
cancers of the larynx and mouth, stomach, kidney, liver and pancreatic cancers [12]. 
Smoking has also been found to impair wound healing, leads to impotence and infertility 
and is particularly harmful to pregnant women and their fetuses, causing complications in 
pregnancy and low birth weight [12]. The Surgeon General’s report released in 2004 gave 
a complete picture of many other smoking related diseases [12].  
1.2.1.1 Singapore’s case – A look into the health effects of smoking in Singapore 
In Singapore, cardiovascular diseases and cancer, of which smoking is a major 
risk factor, are the top two leading causes of premature death and ill-health. In 2010, both 
diseases together accounted for more than one-third (39%) of the total disease burden 
quantified using disability-adjusted life years (DALYs) (Figure 1-4) [18]. 
9 
 
Figure 1-4 Distribution of disability-adjusted life years by broad cause group, 2010  
 
Source: Singapore Burden of Diseases Study 2010  
 
 
Among the mortality caused by cancers, lung cancer is the leading cause of cancer 
death in males and the second in females in Singapore [19], however, the age 







Figure 1-5 Age-standardized mortality rate of lung cancer, Singapore 
 
Source: Singapore Cancer Registry Interim Report. Trends in Cancer Incidence in 
Singapore 2008-2012 
 
1.2.1.2 Health consequences of secondhand smoking 
Besides its direct adverse health impact on the smokers, cigarette smoking can 
also cause negative externalities. Breathing secondhand smoke, also known as 
environmental tobacco smoke or passive smoking, is detrimental to the health of non-
smokers. It can cause harm to the cardiovascular and respiratory systems, and long term 
exposure can even cause cancer [21-23].  
According to reports by the World Health Organization (WHO), an estimated 
600,000 individuals died from exposure to secondhand smoke in 2011 [2], and the 
majority of these deaths occurred in women and children. Exposure of secondhand smoke 
in the workplace is estimated to be responsible for the deaths of 617 employees per year 
in the United Kingdom (UK) in 2003 [24]. Fortunately, with the introduction of laws 
40 

































































prohibiting smoking within office premises in many countries, exposure of secondhand 
smoke in the workplace has been cut down considerably.  
In summary, smoking cessation has many health benefits for smokers and non-
smokers alike. Life expectancy of those who quit smoking at age 35 exceeded that of 
continuing smokers by 6.9 to 8.5 years for men, and for women, from 6.1 to 7.7 years 
[25]. Although it is important to quit smoking as early as possible, evidence shows that 
quitting at any age provides meaningful life extension for smokers [25] and should be 
highly encouraged. 
 
1.2.2 Economic cost of smoking 
Besides its direct impact on health, smoking is a costly problem. The health-
related economic losses due to smoking have been shown to be substantial in many 
countries [26-31].  For example, in the US during the period of 2000–2004, cigarette 
smoking was estimated to be responsible for USD$193 billion in annual health-related 
economic losses. This included nearly US$96 billion in direct medical costs and an 
additional US$97 billion in lost productivity [29]. In the UK, the direct cost of smoking 
to the National Health Service was estimated to be £5.2 billion in 2005-2006 [30].  
As with other illnesses, the economic burden of smoking encompasses the direct 
cost of smoking-related diseases (i.e. expenditures for medical goods and services, e.g. 
medications, doctor visits, and hospitalization), indirect cost or productivity losses due to 
morbidity or mortality, and  intangible cost (i.e. pain and suffering imposed by smoking-
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related diseases and its treatment) [32]. Direct medical cost of smoking related diseases 
have been shown to be substantial [33], but they are only a portion of the total cost of 
smoking to the society. Indirect cost such as losses in labor productivity, fire damage and 
the intangible sufferings of the victims and their families would also add a considerable 
portion to the total cost of smoking [34]. 
1.2.2.1 Societal cost of smoking in Singapore 
In Singapore, using the human capital approach, the societal cost of smoking in 
Singapore was estimated to range from S$673 million to S$839 million in 1997. The 
estimates included the direct cost (payments for hospitalization and health care due to 
smoking) ranging from S$73.8 million to S$74.5 million, morbidity (lost production due 
to illnesses associated with smoking) ranging from S$3.2 million to S$3.5 million and 
mortality cost (lost production from pre-mature mortality due to smoking-related deaths) 
from S$596 million to S$761 million [35]. Even so, the authors believed that the figures 
were underestimates due to the limited range of diseases covered as well as omission of 
other cost such as outpatient care.  
 
1.2.3 Humanistic burden  
To achieve a balanced and comprehensive picture of the impact of healthcare 
interventions, the economic, clinical and humanistic outcomes (ECHO) model [36] is 
commonly used as a framework to assess relevant outcomes [37]. Although much has 
been reported on the clinical and economic burden of smoking, the effect of smoking on 
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quality of life is not as well documented. Some studies have suggested that smoking is 
associated with a lower quality of life, but the results were inconsistent [38-45]. The 
effect of smoking on quality of life has never been evaluated in the local Singapore 
population. Hence, we attempted to evaluate the humanistic outcomes, that is patients’ 
self-assessment of the impact of smoking on their lives and well-being, as well as its 
burden.  
 
1.3 The fight against the smoking epidemic  
Efforts have been carried out by many parties, on the international and local level, 
in its fight against the smoking epidemic. An international treaty on tobacco, the WHO 
Framework Convention on Tobacco Control (FCTC) was adopted by the World Health 
Assembly in May 2003 and by February 2005, it was entered into force. The FCTC calls 
for joint efforts to combat smoking globally, setting minimum standards for tobacco 
control policy and allows for signatories to share best practices internationally [46].  
To provide assistance to countries working towards smoking control, the WHO 
Tobacco Free Initiative (TFI) actively develops guidelines for references. Six evidence-
based tobacco control measures were identified by the WHO as effective in reducing 
tobacco use, known as the MPOWER [1]:  
Monitor tobacco use and prevention policies 
Protect people from tobacco smoke 
Offer help to quit tobacco use 
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Warn people about the dangers of tobacco 
Enforce bans on tobacco advertising, promotion and sponsorship 
Raise taxes on tobacco 
In summary, the WHO TFI believes that treatment of tobacco dependence should 
be part of a comprehensive tobacco-control policy with public measures such as taxation 
and price policies, advertising restrictions, dissemination of information and 
establishment of smoke-free public places. This should go along with an individual 
approach, either using behavioral and/or pharmacological interventions, to treat tobacco 
dependence, as well as providing a supportive environment to encourage smokers in their 
attempts to quit [47]. The various smoking control interventions and their potential 






Higher tobacco prices, usually due to tax increase, have been shown to 
deter potential smokers from starting the habit and also those who are 
currently smoking to reduce their consumptions or to quit completely 
[49-51]. A study by the World Bank showed that every 10% increase in 





While secondhand smoke policies were to protect non-smokers, 
research showed that they also lead to increased quitting among 
smokers [49, 53-55]. Over the last 20 years, smoke-free policies have 
increased significantly, especially in workplaces and more recently, 
also adopted at homes.  
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3. Mass media 
campaigns 
Mass media has the potential of reaching a large segment of the 
population, creating awareness and support. It is an important means of 
changing social norms and ultimately promoting smoking cessation 
[49, 56]. There are some evidence to show that it is useful in adult 
population especially with sustained use [57], and also to prevent 
smoking in young people [58].  
4. Product 
labeling 
Health warning on the packaging of tobacco products has progressed 
from simple, small, weak text warnings 30 years ago to strong graphic 
warnings introduced by Canada in 2010. Growing evidence has shown 
its effectiveness by reinforcing the health messages directly to smokers 
every time they reach for a cigarette [59].  In 2012, Australia was the 
first country to adopt standardized  or “plain” packaging [60] and it is 
currently being considered in other countries. 
5. Marketing 
bans 
According to statistics published in the Tobacco Atlas, over 60% of 
countries have imposed some restrictions on tobacco marketing [1].  
However, there are calls for complete bans on all forms of tobacco 
advertising, marketing, sponsorship and promotion, instead of just 
partial restrictions, in reducing population smoking rates.  




The efficacy of behavioral therapies for the treatment of tobacco 
dependence has been comprehensively reviewed in the United States 
Public Health Service’s (USPHS) Clinical Practice Guideline: 
Treating Tobacco Use and Dependence [61]. Counseling settings may 
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range in complexity from simple physician or health-care provider 
advice to more extensive therapy (e.g. individual [62], group [63], or 




Telephone quitlines provide an important route of access to support 
for smokers, and a Cochrane review showed that call-back counseling 
enhances their usefulness [64]. Quitlines are often featured in anti-
smoking media campaigns and on cigarette packs along with graphic 
warning labels.  
8. Self-help 
materials 
Self-help materials comprise any manual or structured program, in 
written or electronic format, that can be used by individuals in a quit 
attempt without the help of health professionals, counselors or group 
support. Cochrane review showed that self-help may increase quit 
rates as compared to no intervention, although the effect size is likely 
to be small. Evidence also showed that materials that are tailored for 





Newer technologies involve the use of cell phones, internet and other 
electronic devices to deliver smoking cessation counseling. Reach of 
these interventions especially the internet is potentially high. 
However, evidence of its effectiveness is inconsistent, and future 
studies with optimization are called for [66].  
10. Pharmaco
-therapies  
Numerous phamacotherapies have been considered in treating 
tobacco dependence [61]. This includes first line medication such as 
nicotine replacement therapy (NRT) [67], bupropion [68] and 
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varenicline [69], as well as others such as herbal therapies. The 
USPHS Clinical Practice Guideline gave ten points of 
recommendations on “Treating Tobacco Use and Dependence” in 
their 2008 update [61]. A summary of the recommendations is 
attached in Appendix I and is useful for parties interested in offering 
tobacco dependence treatment. Further discussions of first line 
medication will also be given in the following chapters where 
relevant.  
 
1.3.1 Smoking control in Singapore 
Singapore ratified the FCTC on 14 May 2004, but efforts to promote a smoke-free 
lifestyle had started much earlier since the 1970s, with legislations to ban smoking in 
public places and prohibition of tobacco advertising and promotion. The Ministry of 
Health subsequently spearheaded the National Tobacco Control Program (NTCP), a 
comprehensive long-term program for smoking control. It was launched in 1986 with the 
theme "Towards a Nation of Non-Smokers". In 2001, the Health Promotion Board (HPB) 
was formed to oversee and coordinate health promotion efforts including the NTCP [70].  
 NTCP adopts a multi-pronged approach, utilizing strategies including taxation, 
tobacco control legislation [the two main ones are Tobacco (Control of Advertisements 
and Sales) Act and The Prohibition on Smoking in Certain Places Act], public education, 
provision of smoking cessation services and collaborative partnerships with healthcare 
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professionals, workplaces, educational institutions, uniformed groups, youth 
organizations, community and religious groups to promote a smoke-free lifestyle. 
 The efforts of NTCP have helped keep the smoking prevalence in Singapore 
among the lowest in the world, at 14.3% in 2010. However, during the 15
th
 World 
Conference on Tobacco or Health (WCTOH), hosted by Singapore, it was revealed that 
the aim is to bring the nation’s smoking prevalence to below 10% by 2020. To achieve 
this objective, the Chief Executive Officer of HPB, Mr Ang Hak Seng declared that “we 
need to go beyond top-down legislation and mobilize the community to lead the way in 
“de-normalizing” smoking. This we will do by converting smokers to smoke-free 
advocates, selling the business value of a smoke-free environment to entrepreneurs, and 
promoting smoke-free public spaces and neighborhoods.” (Press release from 15th 
WCTOH, HPB, dated 20 March 2012).  
 
1.4 The role of the workplace in the battle against the smoking epidemic  
Internationally, current worksite health promotion goes beyond concerns for 
worksite safety, and encourages a healthy lifestyle and work environment. These include 
efforts to promote smoking cessation, physical activity, healthy nutrition, and reducing 
obesity [71]. Providing smoking cessation in the workplace can improve employees’ 
health, promote healthy living within the society, and may also reduce sickness absence 
in employees as well as increase their productivity [72].  
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From the practical perspective, the workplace is an ideal environment to promote 
smoking cessation as working adults spend a large portion of their waking hours at work. 
In addition, the prevalence of smoking in the working age population is rather high 
(Table 1-1). The advantages of the workplace as a setting for smoking cessation activities 
can be summarized as below: 
1. The ability to reach large numbers of people. 
2. The ability to reach groups who may not normally consult health professionals, 
and hence miss the opportunity of opportunistic smoking cessation counseling. 
For example young healthy adults, as opposed to older adults, already 
presented with smoking-related diseases and hence are seeing physicians to 
treat their condition, and offered smoking cessation counseling as part of their 
treatment.  
3. The potential for people in the workplace to provide peer group support. 
4. A non-smoking working environment encourages people who smoke to quit, 
and promotes abstinence in those who have successfully quit.  
Besides worksite smoking bans [73, 74], smoking cessation efforts in the 
workplace have also included disseminating self-help materials, individual and group 
counseling, offering NRT [75, 76], incentives [77-79] and contests [78]. A Cochrane 
review carried out to evaluate workplace interventions for smoking cessation found 
strong evidence that group programs, individual counseling and pharmacological 
treatment increased cessation rates in comparison to no treatment or minimal intervention 
controls. Self-help interventions and social support were less effective, whereas incentive 
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schemes increased attempts to stop smoking, though there was less evidence that they 
increased the rate of actual quitting [80].  
One of the biggest smoking cessation trials that was carried out is the COMMIT 
(Community Intervention Trial for Smoking Cessation) study. It was a community-level, 
multi-channel, 4-year intervention trial. One community within each of 11 matched 
community pairs (10 in the United States, 1 in Canada) was randomly assigned to 
intervention, the work-site being an important aspect for intervention (along with other 
channels such as health care providers, community smoking cessation resources, and 
media and public education activities) [81]. Although the post-test evaluation focusing on 
work-site showed that smoking restrictive policies were equivalent in both groups, there 
appears to be more smoking cessation activities such as talks and contests in the 
intervention group as compared to the comparison group [81]. Along with other 
community interventions besides work-site intervention, the COMMIT showed that there 
was an increase in the quit rate for light-to-moderate smokers, although this was not seen 
in heavy smokers [82].  
Likewise, the Singapore government recognizes workplaces as excellent 
platforms to develop comprehensive and sustainable health promotion programs. HPB 
provides consultancies to help workplaces set up workplace smoking cessation programs 
(WPSCP). Regular training is conducted to equip facilitators with advocacy skills to 
secure management buy-in and planning skills to implement in-house cessation 
interventions. However, the uptake rate for WPSCP has been low over the years 




1.5 Research gaps, research objectives and thesis organization  
In summary, smoking is a costly problem and poses serious health threats not only 
to smokers, but also to those around them. While the health and economic burden of 
smoking is well known, more work needs to be done to evaluate its humanistic burden 
and to the best of our knowledge, has never been evaluated locally. Therefore, the first 
research objective is to evaluate the humanistic burden of tobacco smoking in Singapore. 
Chapter 2 of this thesis aimed to evaluate the association of smoking status with health-
related quality of life (HRQoL) in a multiethnic Singapore population. 
Recognizing the burden of smoking, extensive research has also been carried out 
on ways to curb this epidemic. The workplace has been identified as one area whereby 
smoking cessation can be carried out to reach a large target population. However, not 
many companies in Singapore choose to carry out WPSCP. Employers support in this is 
thus important and it has been advocated that further research be carried out to identify 
strategies to elicit management support for WPSCP [83].  
To address the problem of poor uptake rate, our next research objective was to 
unearth the reasons behind this and to evaluate ways of addressing it appropriately. 
Hence, in Chapter 3, we aimed to understand employers’ perceived barriers, benefits and 
resources needed for WPSCP. Questions that were raised to the employers were “What 
are the barriers in providing WPSCP?”, “What are the perceived benefits of having 
WPSCP?” and “What resources are needed for implementation of WPSCP?”.  The 
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answering of these questions would allow misconceived barriers to be addressed, 
awareness of the benefits to be raised and appropriate support to be rendered in the 
implementation of WPSCP in Singapore.  
To further increase stakeholder’s buy-in for WPSCP, it is very important that we 
have a good understanding of the employers’ perception on various currently available 
smoking cessation interventions. Although evidence of the effectiveness of the various 
interventions in the workplace has been extensively researched, we would also like to 
find out the employers’ perceived feasibility and willingness to implement the various 
interventions in the workplace. Hence, in Chapter 4 of the thesis, we aimed to determine 
which smoking cessation interventions Singapore employers deem to be effective, 
feasible and willing to implement in their workplace.  
It has been suggested that another way to obtain employers’ buy in into the 
program is to show them that there is a business case in doing so. This has been 
recommended by numerous official guidelines in the implementation of WPSCP [84]. 
We did not find any published study on this locally, hence, in Chapter 5, we aimed to 
evaluate the cost benefit of an employer supported WPSCP in Singapore.  
The studies reported in these chapters on addressing pertinent questions in the 
implementation of WPSCP would hopefully pave the way for future incorporation of 
WPSCP in Singapore’s workplaces. Chapter 6 serves to give a summary of what we have 
found and also future work that needs to be done before we see more WPSCP being 








Chapter 2                                                                                           
Impact of Self-Reported Smoking Status on Health-related 










Smoking is a major avoidable cause of ill health and premature death worldwide.  
Smoking related diseases, including cancer, heart disease, stroke and chronic obstructive 
pulmonary disease (COPD) are among Singapore’s leading causes of death and a burden 
to the country [85]. Smoking cessation has been shown to reduce morbidity and mortality 
[12] and, hence, we postulated that it may also improve HRQoL. HRQoL is the value 
assigned to duration of life as modified by the impairments, functional states, perceptions, 
and social opportunities that are influenced by disease, injury, treatment or policy [86].  
Numerous studies have reported poorer HRQoL among current smokers as 
compared to ex-smokers and never smokers. Using the SF-36 health survey, some studies 
have found current smokers to report consistently poorer health than never smokers and 
ex-smokers in all subscales [38], while others have found such differences only on some 
SF-36 subscales [39, 40, 87]. A prospective cohort study with a 26-year follow-up of 
1658 white men found that participants who had never smoked lived a mean of 10 years 
longer than heavy smokers and among survivors, never smokers had the best scores on all 
RAND 36-Item Health Survey scales [41]. Data from the 2006 Behavioral Risk Factor 
Surveillance System (BRFSS) in the United States involving 17,800 participants, using 
HRQoL measures from the CDC HRQoL-4 and Healthy Days Symptoms Module, 
suggested that never smokers were less likely to report life dissatisfaction, frequent 
anxiety symptoms, frequent depressive symptoms, and frequent sleep impairments, as 
compared with current smokers who made no attempts to quit [42]. 
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However, the results comparing ex-smokers and never smokers appeared to vary. 
While no differences were found between ex-smokers and never smokers on any of the 
SF-36 subscales in a study by Laaksonen et al [40], Bellido-Casado et al found that ex-
smokers reported better HRQoL than non-smokers on the mental health dimensions, 
especially vitality and role emotional [43], whereas Wilson et al found that ex-smokers 
reported significantly lower scores on several SF-36 subscales, namely physical 
functioning, role-physical, bodily pain, general health and vitality, as compared to never 
smokers [38].  
To the best of our knowledge, there is no published study to-date on the 
association of smoking with HRQoL in an Asian general population. Hence, this study 
was conducted in a multiethnic population of Singapore citizens and permanent residents. 
This study aimed to evaluate possible differences in HRQoL, measured using the 
EuroQoL 5-Dimensions (EQ-5D), Short-form 36 Version 2 (SF-36v2) and Health 
Utilities Index (HUI3), according to self-reported smoking status of a sample of 
multiethnic Singaporeans stratified by gender.  
 
2.2 Subjects and methods 
Study participants and study design 
This study used baseline data from a 12-month prospective community-based 
longitudinal follow-up health utilization survey of Singaporeans aged 21 years and above. 
Door-to-door recruitment of participants was carried out, with face to face interviews for 
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baseline assessments at the point of recruitment. Follow-up assessments at 6- and 12-
month were through telephone interviews. Inclusion criteria included Chinese, Malay and 
Indian ethnicity as recorded in the individual’s national registration identity card (which 
reflects paternal ethnicity as at December 2010), resident status, aged 21 and above, 
ability to comprehend any one of the survey languages (English, Chinese and Malay) and 
absence of cognitive impairment as assessed by the recruiters. Quota sampling by age, 
gender and ethnicity was adopted. This study was approved by the SingHealth 
Centralized Institutional Review Board.  
Consenting participants were interviewed using a questionnaire containing the 
Singapore English, Chinese and Malay versions of the EQ-5D, SF-36v2 and HUI3. The 
reliability and validity of these instruments were previously evaluated and found 
acceptable for use in Singapore [88-91].  Smoking status and sociodemographic data 
were assessed at baseline by participants self-report. With regards to smoking status, 
participants were asked to indicate the category that applied to them – “Never smoked 
before”, “Ex-smoker (previously smoked, but has stopped smoking completely)”, 
“Occasional smoker (smoke less than seven cigarettes a week currently)” or “Regular 
smoker (smoke seven or more cigarettes a week currently)”.  
Health related quality of life (HRQoL) instruments 
EuroQoL 5-Dimensions (EQ-5D). The EQ-5D is a generic, preference-based instrument 
developed by the EuroQoL Group. It consists of the EQ-5D descriptive system with five 
dimensions (mobility, self-care, usual activities, pain, and anxiety/ depression), each with 
three levels of response (no problem, some problems and severe problems) as well as a 
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visual analog scale (EQ VAS) that serves to generate a self-rating of HRQoL from 
respondents. A total of 243 health states can be defined by the descriptive system and 
converted to a single summary index by applying a formula that essentially attaches 
weights to each of the levels in each dimension. The utility weight ranges from -0.594 to 
1 (with a higher score indicating better HRQoL) based on the valuation of EQ-5D health 
states from the UK general population using the time trade-off method [92].  
Short-form 36, Version 2 (SF-36v2). The SF-36v2 is a generic health survey with 36 
questions. It yields an 8-subscale profile of functional health and well-being scores as 
well as psychometrically-based physical and mental health summary measures and a 
preference-based health utility index. The 8 subscales are physical functioning (PF), role-
physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning 
(SF), role-emotional (RE) and mental health (MH). The eight scales form two distinct 
higher-order clusters – the physical component summary measure (PCS) and mental 
component summary measure (MCS) [93]. In Singapore, PF, RP, BP, SF and RE scales 
contribute to the physical component of health, while BP, GH, VT, SF and MH 
contribute to the mental component of health [90]. Norm-based scoring was used in this 
study, with scores standardized to a mean of 50 and standard deviation of 10, with a score 
above 50 representing better than average health status and below 50 representing poorer 
than average health status. 
Health Utilities Index Mark 3 (HUI3). The HUI3 is a generic, preference-based measure 
that describes a comprehensive 972,000 health states. It was developed using a 
multiplicative multi-attribute utility function, derived from a representative sample of the 
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Canadian population based on the standard gamble and visual analog scale [94]. Scores 
range from -0.36 for all-worst HUI3 state to 1 for perfect health [94, 95]. Individual 
attributes of the HUI3 are vision, hearing, speech, ambulation, dexterity, emotion, 
cognition and pain.  
 
Statistical analyses 
Descriptive statistics were used to profile the sample sociodemographics (age, 
gender, ethnicity, body mass index (BMI), education, marital and employment status, 
housing type, alcohol consumption as well as presence of chronic medical conditions), 
HRQoL and smoking status at baseline. Analyses were stratified by gender as the 
distribution of smoking status is known to differ by gender. We compared the differences 
in participants’ characteristics by smoking status using chi-square test for categorical 
variables and analysis of variance (ANOVA) test for continuous variables. We evaluated 
the HRQoL measures at both the overall scale and individual attribute levels and defined 
statistical significance at P < 0.05. At the scale level, we conducted multivariate (multiple 
dependent variable) regression analyses for simultaneous analysis of SF-36v2 PCS and 
MCS, HUI3 overall utility, EQ VAS and EQ-5D utility scores as dependent variable. We 
performed multivariate regression analyses of the five dependent variables as a single 
regression model instead of estimating a multiple linear regression for each dependent 
variable separately because this allow us to test the global null hypothesis of no 
association between the explanatory variables and any of the dependent variables without 
inflating type I error rates arising from multiple comparison [96]. At the individual 
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attribute level, we conducted separate multiple linear regression analyses with HUI3 
attributes utility scores and SF-36v2 subscale scores, respectively. As individual attribute 
utility scores are not available for EQ-5D, responses were collapsed into two levels – 
with and without problems and then subjected to multiple logistic regression analyses 
with these dichotomous responses as dependent variables while adjusting for potential 
confounders. We included all explanatory variables which might have an effect on the 
HRQoL in the models and the coefficient of determination (adjusted R
2
) was reported.  
 
2.3 Results  
Subjects 
Of 4670 individuals approached, available and eligible for interview, 3006 
participated, yielding a response rate of 64.4% which was not unusual for door-to-door 
interviews such as this. At 6-month, 2190 subjects remained in the study (dropout rate of 
27%), and at 12-month, 1773 subjects remained in the study (dropout rate of 41% from 
baseline). However, for this study, only the baseline data were used. This was because 
smoking status was not captured in the follow-up surveys. Of 3006 subjects included in 
the analysis, 2113 (70.3%) had never smoked before, 240 (8.0%) were ex-smokers, 132 
(4.4%) occasional smokers and 521 (17.3%) were regular smokers.  
Characteristics of study subjects, by gender, are summarized in Tables 2.1, 2.2 
and 2.3. Statistically significant differences among subjects categorized by their smoking 
status were found for all variables except BMI. Never smokers were less likely to have 
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consumed alcohol within the past 6 months. Ex-smokers were significantly older and had 
more chronic medical conditions. Regular smokers were more likely to be with primary 
school education or less and staying in small public housing. Most females were never 
smokers, whereas regular, occasional and ex-smokers were mostly males. Of the 1499 
males in this study, 727 had never smoked before, 208 were ex-smokers, 104 occasional 
smokers and 460 were regular smokers. Out of the 1507 females, most (1386) were never 
smokers, and 32, 28 and 61 were ex-, occasional and regular smokers respectively. 
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Table 2-1 Characteristics of subjects by smoking status 
    Smoking status   
N (%) unless otherwise stated  
All  
(n = 3006) 
Never smoked 
before  
(n = 2113) 
Ex-smoker                 





 (n = 132) 
Regular smoker
‡
      
 (n = 521) 
P-
value 
Gender            < 0.001 
     Male 1499 (49.9%) 727 (34.4%) 208 (86.7%) 104 (78.8%) 460 (88.3%)  
     Female 1507 (50.1%) 1386 (65.6%) 32 (13.3%) 28 (21.2%) 61 (11.7%)  
Ethnicity            < 0.001 
 Chinese 1501 (49.9%) 1100 (52.1%) 132 (55.0%) 61 (46.2%) 208 (39.9%)  
 Malay 759 (25.3%) 452 (21.4%) 61 (25.4%) 40 (30.3%) 206 (39.5%)  
 Indian 746 (24.8%) 561 (26.5%) 47 (19.6%) 31 (23.5%) 107 (20.5%)  
Mean age (SD) 48.00 (16.45) 47.95 (16.28) 55.33 (16.77) 45.53 (15.84) 45.47 (16.19) < 0.001 
Body mass index (BMI) classification           0.348 
 Underweight (< 18.5 kg/m
2
) 352 (11.7%) 235 (11.1%) 29 (12.1%) 13 (9.8%) 75 (14.4%)  
 Normal weight (18.5 to < 23 kg/m2) 1070 (35.6%) 775 (36.7%) 76 (31.7%) 45 (34.1%) 174 (33.4%)  
 Overweight (23 to < 27.5 kg/m2) 1064 (35.4%) 738 (34.9%) 98 (40.8%) 48 (36.4%) 180 (34.5%)  
 Obese (≥ 27.5 kg/m2). 520 (17.3%) 365 (17.3%) 37 (15.4%) 26 (19.7%) 92 (17.7%)  
Education            < 0.001 
 Primary or less (6 years or less) 1302 (43.3%) 859 (40.7%) 119 (49.6%) 52 (39.4%) 272 (52.2%)  
 Secondary (11 years) 873 (29.0%) 572 (27.1%) 72 (30.0%) 44 (33.3%) 185 (35.5%)  
 Tertiary (14-15 years) 831 (27.6%) 682 (32.3%) 49 (20.4%) 36 (27.3%) 64 (12.3%)  
Housing type            < 0.001 
 Small public housing 2284 (76.0%) 1558 (73.7%) 184 (76.7%) 97 (73.5%) 445 (85.4%)  
 Large public housing 612 (20.4%) 462 (21.9%) 46 (19.2%) 32 (24.2%) 72 (13.8%)  
 Private housing 110 (3.7%) 93 (4.4%) 10 (4.2%) 3 (2.3%) 4 (0.8%)  
Currently married  2081 (69.2%) 1449 (68.6%) 187 (77.9%) 94 (71.2%) 351 (67.4%) 0.018 
Currently employed 1733 (57.7%) 1106 (52.3%) 141 (58.8%) 94 (71.2%) 392 (75.2%) < 0.001 
Presence of chronic medical conditions 1129 (37.6%) 817 (38.7%) 120 (50.0%) 36 (27.3%) 156 (29.9%) < 0.001 
Consumed alcohol within the past 6 months  575 (19.1%) 281 (13.3%) 68 (28.3%) 50 (37.9%) 176 (33.8%) < 0.001 
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Table 2-2 Characteristics of subjects by smoking status for males 
    Smoking status 
N (%) unless otherwise stated  
All 
Never smoked 
before Ex-smoker                 
Occasional 
smoker
† Regular smoker‡      P-
value (n = 1499) (n = 727) (n = 208)  (n = 104)  (n = 460) 
Ethnicity  
          
< 0.001 
 
Chinese 744 (49.6%) 401 (55.2%) 115 (55.3%) 49 (47.1%) 179 (38.9%) 
 
 
Malay 380 (25.4%) 126 (17.3%) 48 (23.1%) 29 (27.9%) 177 (38.5%) 
 
 
Indian 375 (25.0%) 200 (27.5%) 45 (21.6%) 26 (25.0%) 104 (22.6%) 
 Mean age (SD) 48.31  (16.98) 47.18  (17.10) 57.08 (15.87) 47.34 (16.03) 46.37 (16.33) < 0.001 
Body mass index (BMI) classification 
          
0.008 
 
Underweight (< 18.5 kg/m
2
) 133 (8.9%) 43 (5.9%) 26 (12.5%) 8 (7.7%) 56 (12.2%) 
 
 
Normal weight (18.5 to < 23 
kg/m
2
) 513 (34.2%) 258 (35.5%) 63 (30.3%) 37 (35.6%) 155 (33.7%) 
 
 
Overweight (23 to < 27.5 kg/m
2
) 595 (39.7%) 303 (41.7%) 89 (42.8%) 38 (36.5%) 165 (35.9%) 
 
 
Obese (≥ 27.5 kg/m2). 258 (17.2%) 123 (16.9%) 30 (14.4%) 21 (20.2%) 84 (18.3%) 
 Education  
          
< 0.001 
 
Primary or less (6 years or less) 581 (38.8%) 200 (27.5%) 108 (51.9%) 36 (34.6%) 237 (51.5%) 
 
 
Secondary (11 years) 446 (29.8%) 188 (25.9%) 58 (27.9%) 36 (34.6%) 164 (35.7%) 
 
 
Tertiary (14-15 years) 472 (31.5%) 339 (46.6%) 42 (20.2%) 32 (30.8%) 59 (12.8%) 
 Housing type  
          
< 0.001 
 
Small public housing 1129 (75.3%) 504 (69.3%) 155 (74.5%) 75 (72.1%) 395 (85.9%) 
 
 
Large public housing 319 (21.3%) 188 (25.9%) 44 (21.2%) 26 (25.0%) 61 (13.3%) 
 
 
Private housing 51 (3.4%) 35 (4.8%) 9 (4.3%) 3 (2.9%) 4 (0.9%) 
 Currently married  1072 (71.5%) 513 (70.6%) 169 (81.3%) 77 (74.0%) 313 (68.0%) 0.005 
Currently employed 1070 (71.4%) 512 (70.4%) 123 (59.1%) 78 (75.0%) 357 (77.6%) < 0.001 
Presence of chronic medical 
conditions 540 (36.0%) 263 (36.2%) 109 (52.4%) 30 (28.8%) 138 (30.0%) < 0.001 
Consumed alcohol within the past 6 




Table 2-3 Characteristics of subjects by smoking status for females 
    Smoking status 
N (%) unless otherwise stated  
All 
Never smoked 
before Ex-smoker                 
Occasional 
smoker
† Regular smoker‡      
P-value (n = 1507) (n = 1386) (n = 32)  (n = 28)  (n = 61) 
Ethnicity  
          
< 0.001 
 
Chinese 757 (50.2%) 699 (50.4%) 17 (53.1%) 12 (42.9%) 29 (47.5%) 
 
 
Malay 379 (25.1%) 326 (23.5%) 13 (40.6%) 11 (39.3%) 29 (47.5%) 
 
 
Indian 371 (24.6%) 361 (26.0%) 2 (6.3%) 5 (17.9%) 3 (4.9%) 
 Mean age (SD) 47.70 (15.90) 48.36 (15.82) 43.94 (18.22) 38.82 (13.33) 38.69 (13.38) < 0.001 
Body mass index (BMI) classification 
          
0.062 
 
Underweight (< 18.5 kg/m
2
) 219 (14.5%) 192 (13.9%) 3 (9.4%) 5 (17.9%) 19 (31.1%) 
 
 
Normal weight (18.5 to < 23 kg/m
2
) 557 (37.0%) 517 (37.3%) 13 (40.6%) 8 (28.6%) 19 (31.1%) 
 
 
Overweight (23 to < 27.5 kg/m
2
) 469 (31.1%) 435 (31.4%) 9 (28.1%) 10 (35.7%) 15 (24.6%) 
 
 
Obese (≥ 27.5 kg/m2). 262 (17.4%) 242 (17.5%) 7 (21.9%) 5 (17.9%) 8 (13.1%) 
 Education  
          
0.025 
 
Primary or less (6 years or less) 721 (47.8%) 659 (47.5%) 11 (34.4%) 16 (57.1%) 35 (57.4%) 
 
 
Secondary (11 years) 427 (28.3%) 384 (27.7%) 14 (43.8%) 8 (28.6%) 21 (34.4%) 
 
 
Tertiary (14-15 years) 359 (23.8%) 343 (24.7%) 7 (21.9%) 4 (14.3%) 5 (8.2%) 
 Housing type  
          
0.24 
 
Small public housing 1155 (76.6%) 1054 (76.0%) 29 (90.6%) 22 (78.6%) 50 (82.0%) 
 
 
Large public housing 293 (19.4%) 274 (19.8%) 2 (6.3%) 6 (21.4%) 11 (18.0%) 
 
 
Private housing 59 (3.9%) 58 (4.2%) 1 (3.1%) 0 (0.0%) 0 (0.0%) 
 Currently married  1009 (67.0%) 936 (67.5%) 18 (56.3%) 17 (60.7%) 38 (62.3%) 0.398 
Currently employed 663 (44.0%) 594 (42.9%) 18 (56.3%) 16 (57.1%) 35 (57.4%) 0.028 
Presence of chronic medical conditions 589 (39.1%) 554 (40.0%) 11 (34.4%) 6 (21.4%) 18 (29.5%) 0.080 
Consumed alcohol within the past 6 months  135 (9.0%) 105 (7.6%) 8 (25.0%) 6 (21.4%) 16 (26.2%) < 0.001 
†Occasional smoker (less than seven cigarettes a week currently)  
‡Regular smoker (seven or more cigarettes a week currently) 
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Mean HRQoL scores by smoking categories are summarized in Table 2.4. Male ex-
smokers tended to report the lowest HRQoL scores for most of the HRQoL instruments 
compared to other categories of smokers before adjustment of covariates. Without adjustment for 
covariates, females generally had a lower HRQoL as compared to males. This trend is the same 
across all categories of smokers except the ex-smokers, where female ex-smokers did not follow 




Table 2-4 Health-related quality of life (HRQoL) scores by smoking status, stratified by gender 
    Cigarette smoking   
Mean HRQoL scores (SD) 









Total  (n = 3006) (n = 2113) (n = 240) (n = 132) (n = 521) 
Males (n = 1499) (n = 727) (n = 208) (n = 104) (n = 460) 
Females  (n = 1507) (n = 1386) (n = 32) (n = 28) (n = 61) 
EQ-5D Total  0.92 (0.16) 0.92 (0.15) 0.88 (0.20) 0.94 (0.17) 0.93 (0.14) < 0.001 
 
Males 0.93 (0.16) 0.93 (0.16) 0.87 (0.21) 0.94 (0.16) 0.93 (0.14) < 0.001 
  Females  0.92 (0.15) 0.91 (0.15) 0.92 (0.11) 0.93 (0.20) 0.92 (0.18) 0.9634 
EQ VAS  Total  81.1 (13.0) 81.2 (13.0) 78.6 (14.0) 83.1 (13.3) 81.4 (12.5) 0.0053 
 
Males 81.3 (12.9) 82.0 (12.6) 78.1 (14.6) 82.4 (12.9) 81.5 (12.4) 0.0012 
  Females  80.9 (13.1) 80.8 (13.2) 81.8 (8.6) 85.9 (14.5) 80.6 (13.0) 0.2385 
SF-36v2 PCS  Total  51.1 (9.4) 51.0 (9.3) 49.5 (11.1) 51.2 (10.8) 51.9 (8.2) 0.0117 
 
Males 51.4 (9.5) 51.8 (9.3) 48.9 (11.6) 51.2 (11.1) 52.0 (8.1) 0.0007 
  Females  50.7 (9.3) 50.6 (9.3) 53.2 (6.3) 51.0 (10.2) 51.5 (8.7) 0.4270 
SF-36v2 MCS  Total  51.4 (9.1) 51.5 (8.8) 49.4 (10.3) 52.4 (8.4) 51.5 (9.6) 0.0029 
 
Males 51.7 (9.6) 52.2 (9.4) 49.2 (10.5) 52.6 (8.5) 51.7 (9.5) 0.0006 
  Females  51.1 (8.6) 51.1 (8.5) 50.2 (8.8) 51.4 (8.3) 50.2 (10.4) 0.8034 
HUI3  Total  0.87 (0.17) 0.87 (0.17) 0.82 (0.20) 0.88 (0.18) 0.88 (0.15) < 0.001 
 
Males 0.87 (0.17) 0.88 (0.16) 0.81 (0.21) 0.88 (0.18) 0.88 (0.15) < 0.001 
  Females  0.86 (0.17) 0.86 (0.17) 0.87 (0.10) 0.89 (0.18) 0.85 (0.18) 0.7556 
†Occasional smoker (less than seven cigarettes a week currently)  
    ‡Regular smoker (seven or more cigarettes a week currently) 
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Smoking and Overall HRQoL Scores 
For males, the global null hypothesis of ex-smoker, occasional and regular smoker (as 
compared to never smoker) being not associated with the five dependent variables were not 
rejected (P = 0.2170, 0.9778 and 0.4274 respectively). After adjustment for age, ethnicity, BMI, 
education, housing, marital status, work status and presence of chronic medical conditions 
(diabetes, high blood pressure, heart disease, stroke, asthma or other lung disease, cancer), we 
observed that the trend of ex-smokers reporting lower HRQoL persisted: SF-36v2 MCS 
(regression coefficient: -1.60, P = 0.026) and HUI3 utility scores (regression coefficient: -0.024, 
P = 0.040) (reference group: never smokers) (Table 2.5). After adjustment for covariates, regular 
smokers and occasional smokers (as compared to never smokers) also showed a trend of lower 
overall HRQoL scores for all instruments, except SF-36v2 PCS for regular smokers. However, 
this trend did not reach statistical significance.  
As for females, the global null hypothesis of ex-smoker, occasional and regular smoker 
(as compared to never smoker) being not associated with the five dependent variables were also 
not rejected (P = 0.6293, 0.5711 and 0.0825 respectively). After adjustment for covariates, only 
HUI3 utility scores for regular smokers were significantly lower as compared to never smokers 
(regression coefficient: -0.056, P = 0.004). Except the EQ-VAS for occasional smokers and SF-
36v2 PCS for ex-smokers, there was also a trend of lower HRQoL scores as compared to never 
smokers, although not statistically significant (Table 2.6). 
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Table 2-5 Multivariate regression models relating overall health-related quality of life scores with smoking status for males, adjusted 
for covariates 
 Regression coefficients 
  
EQ-5D                   
utility scores  
EQ VAS SF-36v2 PCS SF-36v2 MCS 
HUI3                  
utility scores 
Adjusted for covariates
†      
Constant 0.99 87.35 55.17 52.54 0.93 
Self-reported smoking status (n), (P)
 ‡       
   Never smoked before
 
(n = 727) Reference 
   Ex-smoker (n = 208), (P = 0.2170) -0.021 -0.88 -0.63 -1.60* -0.024* 
   Occasional smoker
 §
 (n = 104),                                   
(P = 0.9778) 
-0.0010 -0.10 -0.63 -0.23 -0.0057 
   Regular smoker
 ‖ (n = 460), (P = 0.4274) -0.0059 -0.80 0.48 -1.03 -0.0081 
Age -0.0019*** -0.17*** -0.12*** -0.051* -0.0026*** 
Ethnicity      
  Chinese Reference 
   Malay 0.0069 1.96* -2.82*** 4.03*** 0.045*** 
   Indian 0.0050 3.10*** -1.64** 3.20*** 0.053*** 
Education       
   Primary or less Reference 
   Secondary 0.012 1.23 0.58 1.42* 0.017 
   Tertiary 0.012 1.46 0.82 1.00 0.015 
Married 0.012 2.29** 1.27* 1.43* 0.025** 
Employed 0.056*** 1.19 3.59*** -0.053 0.053*** 
Presence of chronic disease -0.068*** -6.44*** -3.03*** -4.89*** -0.069*** 
Housing      
   Small public housing Reference 
   Large public housing -0.0019 -0.25 0.21 1.15 0.099 
   Private housing  0.024 3.18 0.44 4.22** 0.064** 
Body mass index 0.00014 0.0054 0.0029 0.000046 -0.000096 
F statistic 28.54*** 26.16*** 28.49*** 18.45*** 39.51*** 
Adjusted R




Adjusted for age, ethnicity, body mass index, education, housing, marital status, work status, presence of chronic medical conditions 
‡
P-value of the global null hypothesis of the explanatory variable (ex-smoker, occasional and regular smoker, respectively) having no association 
with any of the five dependent variables.
 
§
Occasional smoker (less than seven cigarettes a week currently)  
‖Regular smoker (seven or more cigarettes a week currently) 
*P < 0.05  
**P < 0.01 




Table 2-6 Multivariate regression models relating overall health-related quality of life scores with smoking status for females, 
adjusted for covariates 
 Regression coefficients 
  
EQ-5D                   
utility scores  
EQ VAS SF-36v2 PCS SF-36v2 MCS 
HUI3                  
utility scores 
Adjusted for covariates
†      
Constant 1.05 90.00 59.56 49.42 0.99 
Self-reported smoking status (n), (P)
 ‡       
   Never smoked before
 
(n = 1386) Reference 
   Ex-smoker (n = 32), (P = 0.6293) -0.010 -0.038 1.69 -1.23 -0.0095 
   Occasional smoker
 §
 (n = 28),                                        
(P = 0.5711) 
-0.027 2.21 -1.57 -0.62 -0.022 
   Regular smoker
 ‖ (n = 61), (P = 0.0825) -0.031 -2.63 -0.91 -1.35 -0.056** 
Age -0.0026*** -0.13*** -0.16*** 0.030 -0.0031*** 
Ethnicity      
  Chinese Reference 
   Malay -0.00079 -0.19 -3.63*** 2.83*** 0.042*** 
   Indian -0.018* -0.071 -2.61*** 1.53** 0.032** 
Education       
   Primary or less Reference 
   Secondary 0.00086 0.31 -0.27 1.07 -0.0096 
   Tertiary -0.0019 -1.30 -0.52 1.04 0.0039 
Married 0.025** 0.96 2.47*** 0.72 0.031*** 
Employed 0.0093 1.06 1.27** 0.48 0.033*** 
Presence of chronic disease -0.080*** -7.69*** -3.41*** -5.60*** -0.074*** 
Housing      
   Small public housing Reference 
   Large public housing 0.0030 -1.15 -0.86 0.51 0.012 
   Private housing  0.030 1.79 -1.41 3.52** 0.029 
Body mass index -0.000054 -0.019* 0.0023 -0.0033 0.000011 
F statistic 33.81*** 21.98*** 32.37*** 15.83*** 38.80*** 
Adjusted R




Adjusted for age, ethnicity, body mass index, education, housing, marital status, work status, presence of chronic medical conditions 
‡
P-value of the global null hypothesis of the explanatory variable (ex-smoker, occasional and regular smoker, respectively) having no association 
with any of the five dependent variables.
 
§
Occasional smoker (less than seven cigarettes a week currently)  
‖Regular smoker (seven or more cigarettes a week currently) 
*P < 0.05  
**P < 0.01 
***P < 0.001 
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Smoking and Individual HRQoL Attributes  
Results of multiple linear regression models with individual HRQoL attributes are given 
in Tables 2.7 and 2.8. For males, after adjustment for covariates, ex-smokers reported 
significantly lower SF-36v2 GH (regression coefficient: -2.00, P = 0.00, and lower HUI3 vision 
(regression coefficient: -0.022, P = 0.005) as well as HUI3 speech (regression coefficient: -
0.0067, P = 0.024) compared to never smokers. Male regular smokers reported significantly 
higher HUI3 ambulation (regression coefficient: 0.014, P = 0.011) but significantly lower HUI3 
emotion (regression coefficient: -0.013, P = 0.033), whereas male occasional smokers reported 
significantly lower HUI3 pain (regression coefficient: -0.020, P = 0.048) compared to never 
smokers. 
Female ex-smokers, on the other hand, reported significantly higher SF-36v2 RP 
(regression coefficient: 3.75, P = 0.021) compared to never smokers. Female regular smokers 
reported significantly lower SF-36v2 BP (regression coefficient: -2.39, P = 0.037), SF-36v2 VT 
(regression coefficient: -3.05, P = 0.009), as well as HUI3 pain (regression coefficient: -0.033, P 







Table 2-7 Linear regression models relating SF-36v2 scales and HUI3 attributes, and logistic regression model relating EQ-5D 
attributes with adjustment for covariates, for males 




  Never smoked 
before
  
(n = 727) 
   Ex-smoker 
(n = 208) 
   Occasional smoker
†  
(n = 104) 
   Regular smoker
‡
   










-0.86 0.56 0.82 0.39 
 
RP 53.76 -1.03 -0.60 0.076 0.20 
 
BP 57.52 -1.27 -1.56 -0.56 0.19 
 
GH 56.64 -2.00** -0.36 -0.63 0.25 
 
VT 54.17 -0.93 0.020 -0.84 0.15 
 
SF 52.26 -1.17 -0.60 -0.043 0.094 
 
RE 52.68 -0.38 -0.56 0.25 0.082 
 
MH 48.60 -1.42 -0.66 -0.71 0.058 
HUI3 




-0.022** 0.00017 -0.00043 0.070  
 
Hearing 1.00 -0.0047 0.0013 0.0017 0.050 
 
Speech 1.00 -0.0067* -0.0033 -0.00055 0.053 
 
Ambulation 0.99 0.0015 0.0054 0.014* 0.094 
 
Dexterity 0.99 -0.0025 -0.0034 0.0039 0.024 
 
Emotion 0.94 -0.0078 -0.000053 -0.013* 0.10 
 
Cognition 0.99 -0.0081 0.0033 -0.0026 0.17 
  Pain 0.97 -0.0062 -0.020* -0.0068 0.12 
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Odds ratio for reporting problems (95% CI) Pseudo R2 
EQ-5D 


















1.40 (0.94-2.08) 0.80 (0.42-1.53) 1.28 (0.89-1.83) 0.23 
  
Anxiety/ 
Depression    
1.13 (0.71-1.80) 1.58 (0.83-3.00) 1.10 (0.72-1.68) 0.11 
Note: Adjusted for covariates (age, ethnicity, body mass index, education, marital status, work status, presence of chronic medical conditions) 
†Occasional smoker (less than seven cigarettes a week currently)  
‡Regular smoker (seven or more cigarettes a week currently) 
*P < 0.05  
**P < 0.01 








Table 2-8 Linear regression models relating SF-36v2 scales and HUI3 attributes, and logistic regression model relating EQ-5D 
attributes with adjustment for covariates, for females 




  Never smoked 
before
  
(n = 1386) 
   Ex-smoker 
(n = 32) 
   Occasional smoker
†  
(n = 28) 
   Regular smoker
‡
    








-0.87 0.45 -1.59 0.38 
 
RP 57.71 3.75* -0.98 -0.16 0.21 
 
BP 58.95 -0.87 -2.99 -2.39* 0.21 
 
GH 56.28 0.90 -2.58 -1.14 0.24 
 
VT 52.01 -0.35 0.32 -3.05** 0.14 
 
SF 54.53 0.36 -1.00 -1.18 0.094 
 
RE 52.75 2.03 -2.65 -0.62 0.075 
 
MH 46.26 -2.01 -0.38 0.64 0.039 
HUI3 




-0.0011 0.0053 -0.021 0.053 
 
Hearing 1.02 -0.0085 0.00067 -0.0018 0.034 
 
Speech 1.01 0.0064 0.0026 -0.0029 0.055 
 
Ambulation 1.05 0.0090 -0.0028 -0.015 0.13 
 
Dexterity 1.00 0.00022 -0.0029 -0.0020 0.024 
 
Emotion 0.94 -0.013 -0.025 -0.0091 0.084 
 
Cognition 1.00 -0.0022 0.0037 -0.017 0.14 
  Pain 1.00 0.0081 -0.018 -0.033** 0.16 
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Odds ratio for reporting problems (95% CI) Pseudo R2 
EQ-5D 


















1.68 (0.66-4.29) 1.10 (0.34-3.56) 1.86 (0.90-3.85) 0.23 
  
Anxiety/ 
Depression    
1.25 (0.45-3.45) 1.96 (0.71-5.42) 0.95 (0.41-2.21) 0.083 
Note: Adjusted for covariates (age, ethnicity, body mass index, education, marital status, work status, presence of chronic medical conditions) 
†Occasional smoker (less than seven cigarettes a week currently)  
‡Regular smoker (seven or more cigarettes a week currently) 
*P < 0.05  
 
   **P < 0.01 
 
   ***P < 0.001 
 




2.4 Discussion  
In this study, we explored the relationship between self-reported smoking status and 
HRQoL in an urban multiethnic Asian population, stratified by gender. At the overall scale level, 
we found that smoking was associated with a trend of lower HRQoL, although results did not 
reach statistical significance for all instruments. Among male participants, we found that ex-
smokers reported significantly lower SF-36v2 MCS and HUI3 utility scores compared to non-
smokers. Among female participants, we found that regular smokers reported significantly lower 
HUI3 utility scores compared to non-smokers.  
Our findings were supported by studies in other socio-cultural contexts which also 
showed that smoking is associated with lower HRQoL [38-45]. To the best of our knowledge, 
this is the first study that described the relationship between smoking and HRQoL in a multi-
ethnic Asian population. We are aware of a study published in the Korean language that 
evaluated the association between HRQoL, smoking knowledge, smoking attitude, and smoking 
cessation intention but the study was conducted among male smokers only [97]. We are also 
aware of a study published in the Chinese language that evaluated smoking and subjective life 
qualities in students [98], which lacks generalizability to the general population.   
An observation of interest is our finding that male ex-smokers tended to report lower 
HRQoL scores as compared to never smokers. It should be noted that ex-smokers in our study 
were older and presented with more chronic diseases that might decrease their quality of life. It is 
also likely that ex-smokers quit smoking only after experiencing an adverse medical event and 
are thus in worse health.  However, after adjusting for sociodemographic factors and other 
covariates including age and presence of chronic diseases, the SF-36v2 MCS and HUI3 utility 
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scores of male ex-smokers remained statistically lower, compared with never smokers. Similar 
results were found in the BRFSS in the United States, where former smokers were significantly 
more likely than never smokers to be in fair/poor general health and to have frequent physical 
distress, mental distress, depressive symptoms, and pain after adjusting for sociodemographic 
characteristics [99]. Results from Wilson et al in a cross-sectional study of 3010 respondents 
from the South Australian Health Omnibus Surveys also suggested that ex-smokers had lower 
HRQoL than never smokers in several health dimensions including PF, RP, BP, GH and VT [38]. 
The reasons for this observation are speculative, and may be related to nicotine withdrawal 
symptoms, which occur for several weeks after stopping smoking. Unfortunately, we were not 
able to assess the duration of ceasing smoking in our study. Regardless of the reason, lower 
HRQoL in ex-smokers may contribute to the relatively high relapse rate in those who have 
previously stopped smoking, which has been reported as 21% over a 6 to 12 month period after 
ceasing smoking [100]. As smoking cessation is linked to many health benefits such as decreased 
mortality from smoking-associated vascular, neoplastic and respiratory diseases [14], it is 
important that ex-smokers maintain long term abstinence. Public health initiatives could take into 
consideration the issue of lower HRQoL in ex-smokers and provide appropriate counseling and 
support to ensure that those who have quit will not relapse because of poorer HRQoL.  
As for the women, results from the Nurses’ Health Study [101] showed that women 
smokers had lower HRQoL (SF-PCS and SF-MCS) as compared to never and former smokers. 
Regular female smokers in our study also reported a lower HRQoL score, although the results 
were only significant when measured using HUI3. The differences in observation could suggest 
that the effect sizes were smaller among Singaporean women and that the HUI3 was more 
sensitive in picking up the smaller differences compared with the SF-36v2.   
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We recognized several limitations of this study. First, due to the cross-sectional nature of 
this study, we were not able to assess cause and effect relationships in the variables studied. As 
such, a longitudinal study should be performed to determine how baseline smoking status as well 
as change in smoking status over time predict HRQoL. Nonetheless, our study suggests the 
presence of an association between smoking and HRQoL, especially that of ex-smokers, in an 
urban Asian population, a finding of considerable public health interest. Second, information on 
specific smoking related variables (e.g. number of pack days, time since ceasing smoking) were 
lacking. Hence, we were unable to determine if there were a dose-response relationship between 
smoking and HRQoL. Third, smoking status was based on self-report. Studies have shown that 
self-reports tend to underestimate smoking status [102] and the misclassification of smokers into 
the non-smokers group might have weakened the association. Nevertheless, we have seen clear 
trends among the different categories of smoking status across the various HRQoL instruments. 
Hence, our findings were likely to be robust. We also acknowledged that because smokers have a 
higher mortality rate as compared to non-smokers, the smokers (regular and occasional) in this 
study might represent a healthier population of survivors, thus accounting for the small effect 
size when compared with the HRQoL scores of never smokers. Fourth, we have included the 
presence of chronic conditions as a covariate and this may representative over adjustment as 
many of these chronic conditions may be the outcomes of smoking rather than a confounder. 
Nevertheless, our analyses represent a conservative estimate on the effects of smoking on 




2.5 Conclusion  
In conclusion, in this study of an urban multiethnic Asian population, we found that 
smoking was associated with reduced HRQoL, with female regular smokers reporting 
significantly lower HUI3 utility scores and male ex-smokers reporting the lowest scores on most 
scales, with SF-36v2 MCS and HUI3 utility scores being significantly lower compared with 
never smokers. Further research is needed to understand the reasons for these observations, 
which suggests that future public health initiatives should not just emphasize the adverse effects 
of smoking but also incorporate strategies to improve the HRQoL of ex-smokers, with a 
particular interest in males. 
 
2.6 Acknowledgments 
This study was supported by program grant 03/1/27/18/226 from the Biomedical Research 








Chapter 3                                                                                                 
Employers’ Perspective on Perceived Barriers, Perceived Benefits 
and Resource Needs for Implementing Workplace-based Smoking 





Smoking is widely established as a preeminent cause of preventable mortality and 
morbidity. In the workplace, smoking is associated with increased absenteeism and presenteeism 
[103, 104]. As employees spend most of their waking hours at work, it is an ideal environment to 
promote smoking cessation. A smoke-free workplace can assist smokers to quit smoking. 
Moreover, it is also beneficial to non-smoking employees as they would not be subjected to 
second hand smoke which has been shown to be harmful [21-23].  
Although smoking cessation treatments has been shown to be clinically effective [61] and 
offering it in the workplace is cost saving [105, 106], active participation rates by both 
employers and employees varied widely [107]. Despite efforts from HPB, uptake of WPSCP in 
Singapore has been poor (personal communication by HPB). To address the problem of the low 
participation rate by employers in WPSCP, we aimed to explore the perceived barriers, perceived 
benefits and resources needed from the employers’ perspective so that misconceived barriers can 
be addressed, awareness of potential benefits can be improved and appropriate support can be 
rendered.   
 
3.2 Methods 
Design and recruitment 
Semi-structured face-to-face interviews were conducted with company representatives. A 
member of the management, or another staff member who was involved in employee health was 
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chosen to represent their company in these interviews, and when deemed necessary, more than 
one personnel or a team of the above were allowed, but this would be recorded as one interview 
for one company. Respondents were paid a cash token of S$100 in appreciation of their time.  
Recruitment was carried out by Nielsen, a global information and measurement company. 
Pre-recruitment was done via telephone calls using Nielsen’s business listing and referrals.  The 
interviews were conducted by seven trained interviewers from May to November 2011. They 
followed the same interviewer guide to minimize interviewer bias. The interview script was 
developed by the research team with input from Nielsen and comprised of a series of closed and 
open-ended questions. The questions began with a discussion on existing smoking cessation 
efforts in the company, followed by reasons for not implementing WPSCP and the employers’ 
perceived barriers in doing so, whether they see any potential benefits in implementing WPSCP, 
and ended with questions regarding resources needed or demonstrable benefits to be shown for 
continuation of the program.  
Written informed consent to participate and voice recording of the interviews were 
sought. As none of the respondents agreed to voice recording, field notes were taken during the 
interviews instead.  
Data analyses 
The data were analyzed using the grounded theory approach [108], whereby analytical 
categories were identified as they emerged from the data. Two coders (GHP and RXC) worked 
independently following a general guideline. They first familiarized themselves with the raw 
data by iterative reading of transcripts of the field notes. Using a thematic framework, data with 
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similar themes were then identified and assigned codes. Both coders independently entered the 
codes into a codebook, indicating at the same time definitions of the codes, sample quotations 
relevant to the codes, guidelines for use and the relationship(s) with other codes. Both coders 
then came together to develop consensus and finalized the codebook. Where discrepancies 
between the coders remain, a third person (WHL) was enlisted to resolve the discrepancies. The 
last stage involved recoding all transcripts by GHP using the finalized codebook.  
 
3.3 Results 
40 out of 179 companies approached participated (response rate = 22.3%). Reasons for 
refusal were not interested to participate or not allowed to represent company in any survey. 19 
of the 40 companies (47.5%) were in the banking, finance or insurance sector, whereas 21 
companies (52.5%) were in the retail, community, social or personal services sector. 30 of the 
companies (75%) had a staff size of less than 100, whereas the remaining companies had 100 or 
more staff (Table 3-1). We do not have information on the companies that declined as these were 
held by the survey company and considered as confidential.    




(n, %) Fewer than 100 
staff 
100 staff and 
above 
Banking, finance, insurance sectors 15 4 19 (47.5%) 
Retail, community, social and personal 
services sectors 
15 6 21 (52.5%) 




Current efforts in the companies to curb smoking  
None of the companies offered a formal smoking cessation program involving 
professionals to help employees quit smoking at the time of interview. However, one quarter of 
them stated that they had implemented a no-smoking policy, whereby smoking was fully 
restricted within 9 of the companies’ compound, and partially restricted in one company (indoor 
smoking was prohibited but smoking outside the company building was allowed) (Table 3-2). In 
addition, some companies applied limited smoking restrictions, e.g. one company prohibits 
employees from smoking only when they are in uniforms, another company prohibits employees 
from smoking during work but they are free to smoke during breaks.  
Table 3-2 Summary of responses from the 40 companies/ employers interviewed 
Summary of percentages of responses from the employers (n=40) 
 
Smoking cessation efforts in the company 
 
Companies that have a formal smoking cessation program involving professionals to 
help employees quit smoking 
0 
Companies that have a no-smoking policy  25% 
Interest in workplace-based smoking cessation program 
 
Companies that were aware of smoking control resources offered in the community 40% 
Companies that were planning to implement workplace-based smoking cessation 
program in the next 12 months 
50% 
Companies that thought they should take an interest in helping their employees to 
quit smoking 
62.5% 
Companies that stated that there were no barriers or negative consequences in 
implementing a workplace-based smoking cessation program  
22.5% 
 
Perceived barriers in implementing WPSCP 
 Poor participation in the program was perceived as the main barrier in implementing 
WPSCP, as stated by most respondents (67.5% of the companies interviewed) (Table 3-3). 
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Respondents also mentioned that they had never received any requests for WPSCP.  Statements 
made by respondents included “no support from smokers”, “they may ignore the program” and 
“smokers refuse to get involved”.  
Table 3-3 List of barriers in implementing workplace-based smoking cessation program, as 
stated by employers 




Poor employees participation 67.5% 
Smoking is a personal choice 62.5% 
Concerns about inciting negative emotions  62.5% 
Lack of budget  42.5% 
Program is not necessary and not of priority  42.5% 
Affect productivity  30.0% 
Lack of manpower 27.5% 
Lack of awareness 25.0% 
Directions and support not rendered from management   22.5% 
Doubts about the benefits of a workplace-based smoking cessation 
program  
10.0% 
Others such as culture influences < 10.0% 
 
An interesting and pertinent point raised by 62.5% of the respondents was the notion that 
individuals’ choice to smoke or not to should be respected. Statements made by respondents 
included “employees can smoke at their own risk”, “it is their personal choice and preference”.  
Others (62.5%) were concerned about inciting negative emotions such as unhappiness, 
resistance, resentment and objection from the employees who smoke. For example, some 
respondents mentioned that “smokers will feel offended, as to them, their work is not related to 
their smoking habits” and “the human resource department will receive complaints from 
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smokers”. Some companies were also worried that employees may quit if the company is very 
persistent on a smoking ban.  
Fewer than half of the respondents (42.5%) felt that WPSCP would be costly or that the 
company lacked the financial resources for the program. The same number of respondents also 
felt it was not necessary to implement WPSCP or that it was not the company’s priority. Even 
though some companies may have ongoing employee wellness programs, smoking cessation was 
not considered a priority. Additionally, 37.5% of the respondents felt that current smoking 
restrictions within the workplace were already sufficient, with some saying that the office 
building management already has its own smoking restriction policies. 32.5% also felt that 
smoking employees constitute only a small percentage of the staff or deemed their companies too 
small to manage and sustain such a program.  
  A number of the respondents (30%) were concerned that if smokers were banned from 
smoking during work, their productivity would be affected, e.g. “some employees work better 
after a puff” and “it can help them reduce stress”.  Additionally, three companies mentioned that 
WPSCP is not viable for their business or will be disruptive if employees need to be given time 
off to attend the program during working hours. For some sectors of the industry, there was a 
fear that WPSCP will affect the business of the company, e.g. one respondent commented that 
“the club has to cater to smokers and non-smokers”.  
  A lack of manpower and expertise to handle WPSCP within their company was 
mentioned by 27.5% of the respondents. As there is usually no special department or resources 
for the program, the task often falls on someone in the human resource department who has other 
duties and responsibilities.  
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Lack of awareness was cited by one-fourth of the respondents as the reason for not 
implementing WPSCP. They quoted that they “don’t know that such programs exist”. Some also 
stated that they were not sure of the types of resources needed to implement the program.  
 No direction or support from top management was cited by 22.5% of the respondents. 
Four respondents also expressed doubts about the benefits of WPSCP. They would like to see 
concrete cost-benefit information before implementing it. “Putting up a poster provided by HPB 
is easy but if it cost like $1000 per session then it won't be possible to implement as it would be 
too costly for the company”. One respondent from a social service agency believed in self-
regulation. He mentioned that as counselors or social workers, their employees “have to set a 
good example and not smoke when dealing with their clients”. Culture also had a role to play, as 
a Korean company in Singapore interviewed stated that the smoking culture is prevalent among 
Koreans. Some respondents had concerns over fire safety as they were worried that smokers 
might hide in secluded areas to smoke.   
Encouragingly, nine companies actually mentioned that there were no negative 
consequences or no barriers in implementing WPSCP from the companies’ perspective. One 
even mentioned that they hardly employ any smokers because it is against the company’s beliefs 
and ethics. However, most acknowledged that the smokers’ intrinsic motivation was important 






Perceived benefits in implementing WPSCP 
Out of the 40 companies interviewed, fewer than half (40%) were aware of smoking 
control resources offered in the community to help companies set up WPSCP. Encouragingly, a 
few respondents who were aware of the role of HPB indicated that they could engage the help of 
HPB in creating awareness among employees. Half of the respondents (50%) were planning to 
have WPSCP in the next 12 months or were carrying out minimal smoking cessation activities 
such as putting up posters (Table 3-2).  
More than half of the companies interviewed (62.5%) thought that they should take an 
interest in helping their employees to quit smoking. Most (67.5%) mentioned that this is for the 
health of their employees. They were aware of the harms of smoking, mentioning that it causes 
“major illnesses and cancers”. Besides the smokers’ own health, many respondents also 
acknowledged the effect of passive smoking on their family members as well as other non-
smoking colleagues in the company. By introducing WPSCP, 5 companies thought that it will 
also reduce the company’s medical cost and medical claims by employees (Table 3-4).  
Table 3-4 List of benefits in implementing workplace-based smoking cessation program, as 
stated by employers 




Health  67.5% 
Healthy lifestyle, good image, cleaner and safer environment within the 
workplace 
60.0% 
Improved workplace productivity 57.5% 
Reduced cost (company's medical cost and insurance claims, as well as 
smokers' own smoking related cost such as buying cigarettes and increased 
medical fees) 
37.5% 





More than half of the companies (60%) would be glad to promote a healthy lifestyle, 
good image, cleaner and safer environment within the company. Some respondents were 
concerned about the image of the company if their staff smoke, especially those in the service 
sector such as restaurants and social services. One respondent mentioned that “non-smoking is 
consistent with their company’s image and values as they are in the social services industry”.  
Potential to improve the productivity of employees at the workplace was also mentioned 
by more than half of the respondents (57.5%). This included reduced smoking breaks, 
absenteeism and medical leaves, as well as improved work performance.  
When considering the financial cost, besides increased medical cost and company’s 
insurance premiums due to smoking-related illnesses, employers were also concerned for the 
smokers themselves as cigarettes are costly. A few mentioned that it is their social responsibility 
to ensure the wellbeing of their employees as a whole and not just within the company. These 
employers said they would want to heighten awareness of smoking cessation in the workplace 
and create a happier work environment.  
Resources needed to implement WPSCP  
Getting management’s approval topped the list of resources needed to implement 
WPSCP. This was cited by 75% of the respondents (Table 3-5). Next on the list, as cited by 72.5% 
of the respondents was a need of sufficient budget to carry out the program. The respondents 
believed that additional funding will help to cover amongst other things, compensation for time 
taken and travel costs by staff to attend the program, monetary incentives to attend program, 
centralized coordinated efforts from HPB to design, coordinate and implement WPSCP rather 
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than have individual companies manage their own programs. 8 companies also indicated the 
need for the government’s financial support or that there should be co-payment between 
companies and smoking employees.  
Table 3-5 List of resources needed in implementing workplace-based smoking cessation 
program, as stated by employers 




Management’s approval  75.0% 
Budget 72.5% 
Manpower 50.0% 
Details needed in implementation of workplace-based smoking cessation 
program 
47.5% 
Concrete benefits of workplace-based smoking cessation program 25.0% 
Others such as physical resources, e.g. pamphlets and brochures < 10.0% 
 
Half of the respondents mentioned manpower needs for the coordination of WPSCP. The 
committee must set up the program, make sure that it runs smoothly and also keep track of 
demonstrable benefits for the company to ensure the continuation of the program. Some also 
believed that support from the entire company is needed, for example employees must consent to 
participate and provide feedback on the program, as well as peer support from non-smoking 
employees.  
The respondents cited other information needs including: 1) Data on number of smokers 
within the company and number of cigarettes smoked per day. 2) Best practices or model of the 
program. Details on available WPSCP such as the structure, the language the program is 
conducted in, time frame of the program, duration of counseling sessions, the amount of time 
employees have to be away from work, the cost to implement, who to approach for help with 
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implementation, potential side effects after quitting, etc. 3) Concrete data on the benefits of 
WPSCP, e.g. work performance of staff before and after joining WPSCP, uptake rate by smokers, 
level of motivation among smokers, statistics on how WPSCP implemented in other companies 
have helped smokers, e.g. quit rate, reduction in number of cigarettes smoked per day, reduction 
in smoking break length, reduction in medical cost, other evidence of reduced smoking activities 
within the company. 4) Physical resources such as pamphlets and brochures, help and 
information from agencies, workplace health consultants to conduct workshops, etc.    
 
3.4 Discussion 
In this first study of Singapore employers’ perspective on perceived barriers, perceived 
benefits and resource needs for implementing WPSCP, we made several important observations 
that were useful for informing the design of WPSCP to increase its acceptance and uptake rate. A 
summary of the responses provided by the employers are provided in Table 3-2.   
First, we noticed that poor participation was mentioned by majority of the respondents 
(Table 3-3). This was similar to other studies whereby smokers’ motivation levels to quit were 
cited as a problem when carrying out smoking cessation efforts [109]. However, according to the 
nation-wide NHSS among Singaporeans in the year 2007, 38.1% of daily smokers in Singapore 
expressed an intention to quit smoking. This number was even higher at 45.6%, amongst young 
daily smokers aged 18 to 24 years old [6]. The numbers were encouraging in that if those who 
expressed interest enrolled in WPSCP, the number of smokers who eventually quit might be 
higher as compared to not offering workplace program as an alternative smoking cessation 
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avenue. In a survey carried out by the California Tobacco Control Alliance (CTCA) in the US, a 
gap between employees’ needs and employers’ perception was observed, where employees 
expressed a need for WPSCP whereas employers stated that they were never asked by employees 
to provide WPSCP and thus did not see a need [110]. In our study, there was also a similar 
opinion by employer that employees did not request for WPSCP. We are not sure if there is an 
unmet need among the employees locally. This should be determined in future studies.  
Second, an interesting observation from our study was that quite a few companies stated 
that smoking is a personal choice and by implementing WPSCP, they fear inciting negative 
feelings amongst their employees (Table 3-3). This comment was similar to another study that 
interviewed 22 small businesses in the manufacturing-labor and hospitality-service sectors where 
the respondents also expressed reluctance to intervene in employees’ personal health decisions 
[111].  Health professionals from three hospitals in China where a study on barriers in 
implementing smoking policies was carried out, acknowledged that it was unrealistic to ban 
smoking totally in the hospital, as smoking is legal and considered the social-norm [109]. While 
companies could launch WPSCP out of social responsibility, many respondents believed that 
whether the program is successful ultimately depends on the employees themselves. It takes trust 
and work from both the employees and the employers to improve the current condition in the 
workplace.  
Third, there appeared to be a misconception about the prevalence of smoking and 
stereotyping of smokers’ gender was prevalent. For example, one employer noted that “80% of 
staff members are about 20-30 years old. Just a couple of them smoke”, another noted “most 
staff members are woman, they do not smoke”. Given that there is an increasing trend of 
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smokers being younger and women, there is a need to educate employers on the current trend. 
According to the NHSS 2007, daily smoking was most prevalent in young adults aged 18 to 29 
years old as compared to the older age groups [6]. The National Health Surveys also indicated a 
steady increase in the crude prevalence of female smoking from 3.2% in 1998 to 4.2% in 2010 
[7].  
Fourth, we also noted other educational needs of employers (Table 3-5). This included 
concrete data on effectiveness and feasibility of WPSCP. Various cost-effectiveness analyses on 
smoking cessation in the workplace have been carried out and showed that it can result in 
substantial health and economic benefits, as well as reduced workplace absenteeism and 
increased employees’ productivity [112]. Our group has also carried out a cost-benefit analysis 
on implementing a WPSCP in Singapore and showed that it can potentially be beneficial to the 
company, especially if it is carried out in the long run (further discussed in Chapter 5). In 
addition to data on effectiveness and feasibility of WPSCP, guidelines on best practices of 
WPSCP [84] modified to suit Singapore’s context may also be prepared by HPB for sharing with 
companies.  
Fifth, companies had a tendency to rely on top down approaches (e.g. smoking bans by 
government and building management). This suggests an uphill task for policy makers who are 
currently advocating a bottom up approach to tackle the challenges of smoking. This was 
mentioned in the 15
th
 WCTOH (Ministry of Health press release), where it was revealed that 
Singapore aims to reduce its smoking prevalence to below 10% by 2020 from the current 14.3% 
in 2010. To achieve this, previous tough top-down approaches need to be complemented by a 
national ground-up social movement that “de-normalizes” smoking and promotes tobacco-free 
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lifestyle as the social norm. This effort would need to involve the whole community, and 
hopefully address the barriers mentioned above such as low participation and the perception that 
smoking is one’s personal choice. Direct engagement of senior management rather than the 
human resource department is also critical to the successful implementation of WPSCP since 
getting management’s approval was the top most needed resource mentioned by the respondents 
(Table 3-5).  
Finally, there was a demand for financial support from government (Table 3-5) as the 
general perception is that WPSCP is a public good which should be supported with taxpayer’s 
money rather than coming from the operating budget of private companies. This is quite 
common as other studies have also reported such requests for workplace wellness programs 
[113]. The government will need to deliberate on whether more funding should be provided to 
promote WPSCP and how best to disburse those funds. It should be noted that funding is 
currently available in the form of workplace grants by HPB, but lack of awareness, one of the 
barriers identified through this study (Table 3-3), may prevent companies from utilizing the 
support.      
Although our study was conducted among Asian employers, our findings closely mirror 
those from a study conducted in the United States. An interview conducted amongst 15 different 
Californian employers found that when making decisions about whether to implement smoking 
cessation benefits in the company, the employers were most influenced by cost benefit and 
employee demand [110]. Despite cultural differences, these were similar considerations by our 
respondents. Similar in both studies, employers were focused on short-term cost savings and 
skeptical about indirect or long-term cost savings and this has prevented them from 
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implementing WPSCP. One interesting point to note from our study was that although 42.5% of 
the respondents quoted cost as one of the barriers in implementing WPSCP (Table 3-3), 37.5% 
of them also believed that by implementing the program, it will be cost savings to the individual 
as well as the company in terms of reduced medical bill and insurance premiums (Table 3-4). We 
hope that the cost-benefit analysis conducted by our group will be able to convince employers 
that there is a business case in providing WPSCP.  All the more so when 57.5% of the 
respondents believed that their employees’ productivity will be improved with smoking cessation 
(Table 3-4), as compared to 30% who were afraid that the program will bring a negative impact 
on their productivity (Table 3-3). 
Unlike the CTCA survey which found that many employers did not perceive smoking as 
a significant health problem and have limited awareness about resources on smoking cessation 
and its programs [110], our employers were considerably more informed about the potential 
harms of smoking and the benefits of smoking cessation (Table 3-4). More promotion should be 
carried out though, as there is still a lack of awareness on WPSCP in Singapore, as stated by 25% 
of the respondents (Table 3-3). 40% were also unaware of smoking control resources offered in 
the community, although it is available in Singapore under the HPB. The support offered is in 
terms of funding to implement the program, as well as manpower support in terms of counselors, 
quitlines and health care professionals to provide advice. This would be useful to employers who 
cited lack of manpower and requiring resources to implement WPSCP as potential barriers 
(Table 3-3 and Table 3-5).  
A limitation of our study was that we did not recruit participants until data saturation was 
reached. This was due to budget constrain. Hence, some views may not have been captured. 
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Furthermore, given the diversity of the workforce, it was not practical for us to include all sectors 
of the economy in our survey. Hence, some sectors of the economy were not represented. The 
perceptions of all employers or employer types and their needs could not be reflected in our 
study. In addition, it was particularly difficult to recruit participants for this study as many of the 
eligible participants were high ranking executives with busy schedule and other important work 
priorities. However, the strength of our study was its sample size of 40, which was relatively 
large for a qualitative study.  This study would be a good start for relevant agencies in Singapore, 
such as HPB, in devising new strategies to improve WPSCP and ultimately lower the national 
prevalence of smoking to its target of less than 10% by the year 2020. Moreover, the numerous 
similarities between this study and that of another Asian study (although carried out only within 
hospitals) [109], and also the CTCA study among US employers [110], suggest that the results of 
our study may also be relevant to workplaces in other sectors in Singapore, and possibly in other 
countries, although this will need to be confirmed with country-specific surveys.  
 
3.5 Conclusion 
To the best of our knowledge, this was the first study in Singapore to identify perceived 
barriers, perceived benefits and resource needs for the implementation of WPSCP. We believe 
that WPSCP is an important avenue to offer smoking cessation support. We have found a lot of 
similarities despite some differences between this study among Singaporean employers and the 
CTCA study among US employers, suggesting that the results of this study may also be relevant 
globally. We have also provided suggestions to policy makers for improving existing WPSCP 
initiatives in Singapore.  Employers’ responses to the potential for implementing WPSCP were 
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encouraging. By understanding their motivations and barriers to implementation of the program, 
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Chapter 4                                                                                               





4.1 Introduction  
In the earlier chapters, we have outlined the perceived barriers, perceived benefits and 
resource needs of employers for implementing WPSCP. To further increase stakeholder’s buy-in 
for WPSCP, it is very important that we have a good understanding of the employers’ perception 
on various currently available smoking cessation interventions.  
As one of the stakeholders, it is important that employers’ perceptions are taken into 
account [83],  because they would lend greater support to a program that they believe in. In this 
chapter, we aimed to determine which smoking cessation interventions employers consider to be 
effective, feasible and willing to implement in their workplace. We believe that the information 
would be useful in designing WPSCP that is more acceptable to employers. Additionally, we 
would like to evaluate if the perceptions differed by company size and company type.   
 
4.2 Methods 
Study design and questionnaire 
Forty semi-structured face-to-face interviews were conducted with employers. Details of 
the study design and recruitment have been outlined in Chapter 3. Briefly, recruitment was 
carried out by Nielsen, a global information and measurement company. Personnel from the 
management or those involved with employee health were chosen to represent their companies in 
these interviews. They were asked a series of closed and open-ended questions to elicit their 
views on smoking cessation interventions. These included: 
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1) Initial open-ended question: To get the employers thinking about possible smoking cessation 
options, respondents were asked “What do you think employers could or should do to help their 
employees quit smoking, if any?”  
2) Rating of preferred smoking cessation options: Employers were then asked to rate ten 
different smoking cessation interventions within their workplace based on perceived 
effectiveness, perceived feasibility and willingness to implement, respectively. The questions 
were “Do you think the interventions will be effective if implemented in your company?” 
(Answer options: not at all effective/ quite effective/ moderately effective/ very effective/ don’t 
know or not sure), and “For each intervention, please state whether the method might be feasible 
in your company?”, “For each intervention, please state whether you are willing to implement 
them within your company?” (Answer options: yes/ no/ don’t know or not sure) 
Data analyses 
Qualitative responses were subjected to thematic analysis by two independent coders. 
Discrepancies in coding were reconciled through discussion. 
We reported the percentages of respondents who perceived an intervention to be effective, 
feasible and willingness to implement these interventions within their company (yes, no, don’t 
know/ not sure). Due to the small number of respondents, the options “quite effective”, 
“moderately effective” and “very effective” were combined into one option as “effective”. We 
also reported the relative rankings of the 10 interventions based on the percentages of 
respondents who perceived the interventions to be effective, feasible and willing to implement 
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them. The responses were also stratified by company size and company type. Fisher’s exact test 
was performed to test whether differences between the subgroups were statistically significant.  
Subgroup analysis by stratifying company size 
To evaluate the impact of company size, we stratified the companies into two subgroups - those 
with 100 staff members or more (large companies), and those with less than 100 staff members 
(small companies).  
Subgroup analysis by stratifying company type 
To evaluate the impact of company type, the companies were stratified into two subgroups - 
Companies in the banking, finance and insurance services (B, F, I) as well as those in the retail 
trade, community, social and personal services (R, C, S, P).                
     
4.3 Results 
40 out of 179 companies approached participated (response rate = 22.3%). 30 of the companies 
(75%) had a staff size of less than 100, whereas the remaining 25% (10 companies) had 100 staff 
and above. 19 (47.5%) were from the banking, finance or insurance sector, while 21 (52.5%) 









(n, %) Fewer than 100 
staff 
100 staff and 
above 
Banking, finance, insurance sectors 15 4 19 (47.5%) 
Retail, community, social and personal 
services sectors 
15 6 21 (52.5%) 
Total (n, %) 30 (75%) 10 (25%) 40 (100%) 
 
1) Initial open-ended question 
Interventions suggested by employers included creating awareness via posters, 
organization of smoking cessation talks, structured smoking cessation program with professional 
help, offering incentives for successful quitters, contests to quit smoke, providing smoking 
cessation aids, and tighter smoking policies within the company.  
2) Rating of preferred smoking cessation options  
Effectiveness 
Smoking cessation talks was considered effective by the highest percentage of 
respondents (82.5%), followed by individual counseling (70%), on-site group smoking cessation 
counseling (65%), and contests or incentives (65%). Prescription medication was considered 
effective by the lowest percentage of respondents (42.5%) (Table 4-2).  
Feasibility 
With regards to feasibility, smoking cessation posters were considered feasible by the 
highest percentage of employers (75%), followed by smoking cessation talks (72.5%) and 
contests or incentives (70%). Offering prescription medication to their employees was 
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considered feasible by the lowest percentage of respondents (40%) followed by off-site smoking 
group smoking cessation counseling (42.5%) (Table 4-2).  
Willingness 
In terms of willingness to implement smoking cessation intervention, disseminating 
posters within the workplace had the highest percentage of respondents who were willing to 
implement (80%) followed by smoking cessation talks (77.5%). Prescription medication had the 
lowest percentage of respondents who were willing to implement (27.5%) followed by off-site 
group smoking cessation counseling (35%), nicotine replacement therapy (42.5%), as well as no 
smoking policy, contests/ incentives and telephone quitlines (all 47.5%) (Table 4-2).  
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Table 4-2 Percentage of employers who perceived the following smoking cessation interventions to be feasible, effective and are 
willing to implement them in their workplace 
Interventions 
Effectiveness (%) Feasibility (%) 












No smoking policy 62.5 35.0 2.5 55.0 42.5 2.5 47.5 45.0 7.5 
Contests/ Incentives 65.0 30.0 5.0 70.0 20.0 10.0 47.5 47.5 5.0 
Smoking cessation posters 60.0 35.0 5.0 75.0 25.0 0.0 80.0 20.0 0.0 
Smoking cessation talks 82.5 15.0 2.5 72.5 22.5 5.0 77.5 20.0 2.5 
On-site group SCC 65.0 22.5 12.5 50.0 47.5 2.5 45.0 47.5 7.5 
Off-site group SCC 55.0 35.0 10.0 42.5 50.0 7.5 35.0 60.0 5.0 
Individual counseling 70.0 20.0 10.0 50.0 37.5 12.5 50.0 42.5 7.5 
Nicotine replacement therapy 62.5 30.0 7.5 62.5 35.0 2.5 42.5 45.0 12.5 
Prescription medication 42.5 37.5 20.0 40.0 45.0 15.0 27.5 50.0 22.5 
Telephone quitlines 57.5 35.0 7.5 60.0 30.0 10.0 47.5 47.5 5.0 









Differences in company sizes 
Except for no smoking policy, a higher percentage of large companies were likely to 
think that smoking cessation interventions are effective compared to small companies. However, 
the differences between company sizes were not of statistical significance for all ten smoking 
cessation interventions (Table 4-3).  
A similar trend was observed with a higher percentage of larger companies perceiving the 
interventions as feasible, except for non-smoking policy. In the case of feasibility of 
dissemination of posters within the workplace, statistical significance was observed for different 
company sizes (Table 4-3).  
Large companies once again appeared to be more willing to implement most 
interventions except for smoking cessation policy. However, large companies were less willing 
to implement on-site group smoking cessation counseling as compared with small companies, 
although this was not reflected for perceived effectiveness and feasibility. All differences in 
willingness to implement did not reach statistical significance (Table 4-3). 
76 
 
Table 4-3 Perception on feasibility, effectiveness and willingness to implement individual smoking cessation strategies in their 









































Small (n=30) 70.0 60.0 50.0 76.7 60.0 46.7 60.0 56.7 40.0 50.0 
Large (n=10) 40.0 80.0 90.0 100.0 80.0 80.0 100.0 80.0 50.0 80.0 
No 
Small 26.7 36.7 43.3 20.0 26.7 40.0 26.7 33.3 40.0 40.0 
Large 60.0 10.0 10.0 0.0 10.0 20.0 0.0 20.0 30.0 20.0 
DN/ NS 
Small 3.3 3.3 6.7 3.3 13.3 13.3 13.3 10.0 20.0 10.0 
Large 0.0 10.0 0.0 0.0 10.0 0.0 0.0 0.0 20.0 0.0 
p 










Small 56.7 66.7 66.7 66.7 43.3 33.3 43.3 53.3 33.3 53.3 
Large 50.0 80.0 100.0 90.0 70.0 70.0 70.0 90.0 60.0 80.0 
No 
Small 40.0 26.7 33.3 26.7 53.3 60.0 40.0 43.3 53.3 36.7 
Large 50.0 20.0 0.0 10.0 30.0 20.0 30.0 10.0 20.0 10.0 
DN/ NS 
Small 3.3 6.7 0.0 6.7 3.3 6.7 16.7 3.3 13.3 10.0 






















Small 50.0 43.3 73.3 73.3 46.7 30.0 46.7 40.0 26.7 36.7 
Large 40.0 60.0 100.0 90.0 40.0 50.0 60.0 50.0 30.0 80.0 
No 
Small 40.0 53.3 26.7 23.3 43.3 63.3 43.3 46.7 53.3 56.7 
Large 60.0 30.0 0.0 10.0 60.0 50.0 40.0 40.0 40.0 20.0 
DN/ NS 
Small 10.0 3.3 0.0 3.3 10.0 6.7 10.0 13.3 20.0 6.7 
Large 0.0 10.0 0.0 0.0 0.0 0.0 0.0 10.0 30.0 0.0 
p 
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DN/ NS don’t know/ not sure  
SCC smoking cessation counseling  
NRT nicotine replacement therapy  




Differences in company types 
In general, a higher percentage of companies in the retail, community, social and personal 
services considered the various smoking cessation interventions as effective compared to the 
banking, finance or insurance sector. An exception was for incentives and contests, NRT and 
prescription medication, where the reverse was observed. However, the differences did not reach 
statistical significance for all interventions ( 
Table 4-4).  
As with effectiveness, we observed a similar trend for feasibility of implementation of the 
interventions. The only exception in this case was prescription medication, whereby a smaller 
percentage of companies in the retail, community, social and personal services thought it feasible 
as compared to the banking, finance or insurance sector. The only statistically significant 
difference in perceived feasibility between the company types was for on-site group cessation 
counseling ( 
Table 4-4).  
A difference in willingness to implement smoking cessation interventions was observed 
between company types, with statistically significant differences in willingness to implement 
smoking cessation talks and individual counseling. In general, the banking, finance or insurance 




Table 4-4 Perception on feasibility, effectiveness and willingness to implement individual smoking cessation strategies in their 
workplace (stratified by company type) 
  
 






































B, F, I (n=19) 52.6 73.7 47.4 73.7 52.6 47.4 57.9 63.2 47.4 47.4 
R, C, S, P (n=21) 71.4 57.1 71.4 90.5 76.2 61.9 81.0 61.9 38.1 66.7 
No 
B, F, I 42.1 15.8 42.1 21.1 26.3 36.8 26.3 26.3 36.8 47.4 
R, C, S, P 28.6 42.9 28.6 9.5 19.1 33.3 14.3 33.3 38.1 23.8 
DN/ NS 
B, F, I 5.3 10.5 10.5 5.3 21.1 15.8 15.8 10.5 15.8 5.3 
R, C, S, P 0.0 0.0 0.0 0.0 4.8 4.8 4.8 4.8 23.8 9.5 
p 










B, F, I 52.6 57.9 63.2 57.9 31.6 31.6 42.1 57.9 42.1 52.6 
R, C, S, P 57.1 81.0 85.7 85.7 66.7 52.4 57.1 66.7 38.1 66.7 
No 
B, F, I 42.1 26.3 36.8 36.8 63.2 57.9 42.1 42.1 52.6 42.1 
R, C, S, P 42.9 14.3 14.3 9.5 33.3 42.9 33.3 28.6 38.1 19.1 
DN/ NS 
B, F, I 5.3 15.8 0.0 5.3 5.3 10.5 15.8 0.0 5.3 5.3 
R, C, S, P 0.0 4.8 0.0 4.8 0.0 4.8 9.5 4.8 23.8 14.3 
p 
    
0.040 


















B, F, I 36.8 36.8 68.4 57.9 31.6 26.3 26.3 31.6 21.1 31.6 
R, C, S, P 57.1 57.1 90.5 95.2 57.1 42.9 71.4 52.4 33.3 61.9 
No 
B, F, I 52.6 52.6 31.6 36.8 63.2 68.4 63.2 57.9 63.2 63.2 
R, C, S, P 38.1 42.9 9.5 4.8 33.3 52.4 23.8 33.3 38.1 33.3 
DN/ NS 
B, F, I 10.5 10.5 0.0 5.3 5.3 5.3 10.5 10.5 15.8 5.3 
R, C, S, P 4.8 0.0 0.0 0.0 9.5 4.8 4.8 14.3 28.6 4.8 
p 
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DN/ NS don’t know/ not sure  
B, F, I Banking, finance, insurance sector 
R, C, S, P Retail, community, social and personal services sector 
SCC smoking cessation counseling  
NRT nicotine replacement therapy  
p P-value for differences, using the Fisher’s exact test to compare the responses (yes, no, don’t know/ not sure) between companies 





In this study to evaluate the perception of employers towards existing smoking 
cessation interventions, we have identified those interventions that were considered most 
effective and feasible as well as having the highest percentage of respondents who were 
willing to implement it, which is likely to be best available surrogate to actual 
implementation of the interventions in workplaces.  
A few interesting findings were observed. First, the percentage of respondents 
who were willing to implement an intervention is not always as high as the percentage of 
respondents who felt the intervention to be effective or the percentage of respondents 
who felt the intervention to be feasible. For example, 62.5% of respondents felt that 
nicotine replacement therapy was effective as well as feasible yet only 42.5% were 
willing to offer it to their employees.  
However, it was clear that if an intervention was felt to be effective or feasible by 
a lower percentage of respondents, then the willingness to implement would also be 
lower. Prescription medication had the lowest percentages of employers who deemed it 
effective (42.5%), feasible (40%), and hence, only 27.5% of the employers were willing 
to offer it. This was followed by off-site group smoking cessation counseling, with only 
55% of the employers viewing it as effective, 42.5% feasible, and only 35% were willing 
to implement it.    
Although we did not probe the reasons for perceived low feasibility and 
willingness to implement the interventions during the time of interview, we did identify 
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factors that the employers perceived as barriers and resource needed in another section of 
the interview (discussed previously in Chapter 3).  For example, there were concerns 
about a lack of budget and manpower to carry out the program, which might affect the 
perceived feasibility and hence willingness of implementing it within their company. 
Offering prescription medication might be one example where cost is an issue to 
employers, and off-site group smoking cessation counseling the other example of being 
more resource intensive in terms of manpower coordination. In view of this observation 
and suggestions provided in Chapter 3, public health decision makers may need to 
deliberate on ways to make smoking cessation activities more feasible in the workplace. 
Second, there appeared to be a discrepancy between what respondents considered 
to be effective within the company versus evidence suggested in the literature. Briefly, a 
review carried out by the Cochrane group to evaluate workplace interventions for 
smoking cessation found strong evidence that group programs, individual counseling and 
pharmacological treatment increased cessation rates in comparison to no treatment or 
minimal intervention controls. Self-help interventions and social support were less 
effective, whereas incentive schemes increased attempts to stop smoking, though there 
was less evidence that they increased the rate of actual quitting [80]. Despite evidence of 
effectiveness, prescription medicines were considered effective by only 42.5% of the 
respondents. The percentage of respondents who cited that they do not know or were not 
sure of the effectiveness of prescription medication was also highest at 20%. This 
suggests that when service providers or policy makers recommend a WPSCP, they should 
incorporate data on effectiveness of the interventions to address any lack of awareness of 
misperception with regards to effectiveness.  
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Third, we observed a need for targeted promotion strategies by company type as 
perceived effectiveness, perceived feasibility and willingness of implementing smoking 
cessation strategies differed between those in the retail, community, social, personal 
services and those in the banking, finance or insurance sector, as well as between small 
and large companies. It has been noted that companies’ characteristics such as size, 
setting and employees’ demographics may affect the effectiveness and extent of WPSCP 
implementation [83, 114]. For example, Hughes et al found that larger workplaces and 
those that employ a wellness staff had more cessation activities. Restaurants, bars and 
lounges had few cessation practices in place whereas warehouses/factories and hospitals 
or healthcare facilities were more likely to refer violators to smoking cessation services 
[114]. The results may be applicable not only in Singapore’s context, but also workplaces 
in other countries. More research could perhaps be carried out to determine the 
characteristics of workplaces that promote a smoking cessation culture.  
To the best of our knowledge, this is the first study to evaluate perceived 
effectiveness, feasibility and willingness to implement smoking cessation interventions 
within Singapore. However, we acknowledged that the companies are not meant to be 
representative of all the companies in Singapore. Due to resource and manpower 
limitation, we were not able to survey a representative set of companies. However, we 
have included in our interviews industries with varying smoking prevalence based on 
overseas data. Similar smoking prevalence by industry or occupation data was not 
available locally. Another limitation of this study was our small sample size. This study 
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was meant to be part of a qualitative WPSCP study and the numbers needed for 
qualitative study is defined by response saturation rather than powered by statistical 
considerations. We also had difficulty recruiting bigger companies for this qualitative 
interview as many expressed that they were bounded by company rules. However, we 
managed to find meaningful differences between small and big companies, as well as 
company types.   
 
4.5 Conclusion 
In this study, we have identified employers’ perceived effectiveness, feasibility 
and willingness to implement of ten smoking cessation interventions within the 
workplace. We found that disseminating smoking cessation posters and offering talks 
within the workplace were most likely to be implemented, based on the percentages of 
employers who were willing to implement these interventions. On the other hand, 
offering prescription medication and off-site group smoking cessation counseling were 
the least likely to be implemented. We have also found differences in company size and 
types, with larger companies and those in the retail, community, social and personal 
services sector perceiving most interventions as more effective, feasible and were more 
willing to implement them as compared to smaller companies and those in the banking, 
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Chapter 5                                                                                         
Evaluating the Cost-benefit of a Workplace-based Smoking 





Efforts have been made to quantify the cost of smoking in the workplace [115-
118]. This is because smoking causes many diseases, which will, in turn, affect the work 
performances of smokers at their work places. Smokers tend to be poorer in health 
compared to people who are not exposed to the environmental tobacco smoke [119]. As a 
result, absenteeism among smokers is approximately 21-95% higher than non-smokers 
[106].  Moreover, smoking breaks are predicted to span over 30 minutes per day for each 
employee, affecting their work productivity [106]. In addition, there may be increase in 
insurance premiums due to medical conditions, early retirement due to premature 
morbidity or mortality, increased facility costs for ventilation systems, smoking-related 
fire damages, increased accidents and workers’ compensation costs, as well as a negative 
effect of second-hand smoke on other employees [23, 103, 104, 120].  
In a study carried out in Scotland, the annual cost of employee smoking was 
found to be about £450 million (US$ PPP 265 million) in lost productivity due to absence 
from work, smoking breaks and fire damages [117]. Similar analyses found that the total 
cost of smoking among working adults in Taiwan were approximately US$1032 million. 
This was due to US$733 million from lost productivity, US$184 million from increased 
sick leave, US$81 million from environmental tobacco smoke and US$34 million from 
occupational injuries [118]. 
As employees spend a substantial amount of their waking hours at work, the 
workplace is an ideal environment to promote smoking cessation. However, active 
participation rates by employers and employees in WPSCP vary widely [107]. One of the 
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ways in which we hope to address the poor uptake rate is to generate local evidence for 
the cost-effectiveness of smoking cessation interventions. Providing proof of cost-
effectiveness may encourage employers to provide more workplace smoking cessation 
activities and other incentives to increase uptake rate.  Hence, this study aimed to 
evaluate the potential costs and benefits of a WPSCP in Singapore from the employers’ 
or companies’ perspective.  
 
5.2 Methods 
Study design                        
Decision tree analysis was used to model the one-year costs and benefits of a 
WPSCP from the companies’ perspective. A short-term perspective was taken due to the 
lack of a life-time economic simulation model that has been validated for use in 
Singapore. We considered four smoking cessation regimens that could be offered by the 
companies – 1.) smoking cessation counseling alone, 2.) smoking cessation counseling 
plus the use of nicotine replacement therapy (NRT), 3.) smoking cessation counseling 
plus bupropion, or 4.) smoking cessation counseling plus varenicline.  
The decision tree is shown in Figure 5-1 with the four branches representing the 
four treatment arms. Each treatment arm has two possible outcomes: the employee is 
either successful (“Quit”) or unsuccessful in quitting (“Smoke”) after one year. The 
probability of quitting with each treatment arm is represented by “Q” and the quit rates 
depend on the effectiveness of the respective smoking cessation regimens. “1-Q” is thus 
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the probability that the employee failed to quit within each treatment arm. The payoff for 
each “Quit” node was calculated as “Savings” for the company as the employee has 
succeeded in quitting, minus the costs associated with the respective treatments (denoted 
by “CostTx”). Payoff for the “Smoke” node on the other hand, will be “SavingsNone” as 
the employee was unsuccessful in quitting, minus “CostTx” as treatment costs will still 
be incurred. The expected value of payoff for each treatment arm was then calculated, 
representing the net benefit to the company. A positive net benefit value indicates a 
saving to the company, whereas a negative value indicates cost to the company. 
In the base-case analysis, all treatment costs and savings were assumed to be 
borne solely by the company and costs and benefits were computed over one year. As the 
duration of the analyses did not exceed a year, discounting was not applied. The decision 
tree was constructed in TreeAge Pro Suite 2009 (Figure 5-1).  
               
Figure 5-1 Decision tree analysis of a workplace-based smoking cessation program 
NRT nicotine replacement therapy, Q probability of quitting, CostTx cost of treatment 
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Smoking cessation regimens  
As described above, four treatment regimens were considered – counseling alone, 
counseling plus either NRT, bupropion or varenicline.  
1. Counseling 
According to the USPHS’s clinical practice guideline on Treating Tobacco Use and 
Dependence, even brief physician advice, averaging 3 minutes significantly increases 
long-term smoking abstinence rates of 10.2% as compared to 7.9% in the control group 
without any advice or counseling [61]. We modeled for four counseling sessions in our 
study in accordance with the guideline’s recommendation. Actual quit rates vary 
according to the settings for counseling sessions (e.g. individual, group, or telephone 
counseling), personnel who conducted the counseling (e.g. physicians, pharmacists or 
trained nurses) and length of counseling sessions. Nevertheless, all have consistently 
been shown to be effective [61] and sensitivity analyses will be carried out on a range of 
quit rates.  
2. Nicotine Replacement Therapy (NRT) 
NRT relieves cravings and withdrawal symptoms by releasing controlled amounts of 
nicotine into the body. A course of therapy involves going through steps of weekly 
intervals with reducing nicotine doses to slowly wean it off. In Singapore, NRT is 
available in several dosage forms, namely gums, lozenges, patches and inhalers. Those 
who smoke more than 20 cigarettes a day will need a 4mg gum, whereas those smoking 
less than 20 cigarettes a day would be on the 2 mg gum. Meanwhile, lozenges are 
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available in 1mg dosage form. It is recommended to use 8-12 pieces of gums or lozenges 
daily for 3 months, before a gradual reduction to 4-6 pieces a day for 2 more weeks, and 
finally to use 1-3 pieces a day for the next 2 weeks with gradual reduction until complete 
cessation. For the purpose of this study, we assumed that an average of 10 pieces a day 
were used for the first 3 months, with gradual reduction to 5 pieces for the next 2 weeks 
and 2 pieces for the last 2 weeks. The recommended dose for nicotine patch therapy is 
15mg patch daily for the first 8 weeks, decreased to 10mg patch daily for the next 2 
weeks and subsequently the 5mg patch for the last 2 weeks. As for the inhaler, the 
recommendation is to use 6-12 cartridges for the first 8 weeks (we used the mid-point of 
9 cartridges), 3-6 cartridges (we used the mid-point of 5 cartridges) for the next 2 weeks, 
followed by 1-3 cartridges (we used the mid-point of 2 cartridges) for the last 2 weeks, 
with gradual reduction until complete cessation [121]. Sensitivity analyses were carried 
out for a range of gums, lozenges and inhalers used. We pooled the results for the 
different types of NRTs as one treatment arm, using market share data provided by IMS 
Health to calculate the proportion of the different NRT dosage forms used.  
3.  Bupropion 
Bupropion is thought to work on the brain pathways involved in addiction and 
withdrawal. For smoking cessation, it is dosed at 150mg per day for the first 3 days, and 




Varenicline is a selective nicotinic receptor partial agonist. It is given at a dosage of 
0.5mg from day 1 to day 3, followed by 0.5mg twice daily from day 4 to day 7, then 1mg 
twice daily till week 12 to aid in smoking cessation [123].  
Quit rates 
For counseling alone, we followed the USPHS guidelines and adopted 10.2% as 
the baseline value of one-year quit rate. We computed the quit rates for NRT, bupropion 
and varenicline using Cochrane reviews. According to Silagy et al, the relative risk of 
abstinence from smoking for any form of NRT relative to control is 1.58 [67]. Hence the 
computed one-year quit rate of counseling plus NRT is 16.1% (1.58×10.2%). Hughes et 
al reported bupropion’s relative risk of abstinence from smoking as 1.69 as compared to 
control [68], thus giving us a quit rate of 17.2%. Varenicline’s relative risk of abstinence 
from smoking was reported as 2.33 as compared to control [69], hence the computed quit 
rate would be 23.8%.  
Cost estimates 
All cost was valued as US$1 = S$1.08 based on Purchasing Power Parity (PPP) 
published in The Economist in 2011 [124]. We modeled our WPSCP according to the 
structure of a program by the HPB. Briefly, an initial smoking cessation awareness 
workshop was carried out in the company, followed by recruitment of smoking 
employees who were willing to quit into a 12-week smoking cessation program, with 4 
sessions of counseling distributed over this period, and smoking cessation aid offered as 
per required by the participants.  
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Counseling cost was the average of market prices in Singapore. This was 
estimated at a total cost of S$48 (US$ PPP 44) per employee over 4 sessions. We did a 
search of the counseling programs offered by various institutions in Singapore and found 
that the program varied, with most offering a one-time smoking cessation awareness talk 
to all employees, while others offered additional follow up with one-to-one counseling or 
group counseling at the workplace for employees who are ready to quit. Alternatively, 
they may also attend off-site (i.e. not at the workplace) counseling sessions at polyclinics, 
hospitals or retail pharmacies. For the purpose of this paper, we assumed counseling 
sessions to be equal in terms of length, frequency and efficacy across all settings.  
Pharmacotherapy costs were based on Singapore market share data obtained from 
IMS Health for the year of 2011. The price of NRT was the weighted average price of 
nicotine gums, lozenges, inhalers and patches. The full course of 12 weeks of NRT was 
calculated to be S$617 (US$ PPP 571). Price of one tablet of bupropion marketed under 
the brand Zyban™ was S$2.20 and hence the cost of a full bupropion course was S$363 
(US$ PPP 336) following the dosing schedule as described above. Varenicline is 
marketed under the brand Champix®. The full course of varenicline was estimated at 
S$660 (US$ PPP 611), where the starter pack for the first 2 weeks cost S$100, and the 
cost per 1mg tablet for the subsequent weeks was S$4 per tablet.  
Cost savings estimates  
The human capital approach was used to calculate cost savings if an employee 
were to quit smoking. Savings (if any) were estimated to be due solely to the elimination 
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of productivity loss which we defined as a combination of smoking breaks and increased 
absenteeism in employees who smoke.  
1. Productivity loss due to smoking breaks  
We calculated the working days per year for an average employee as 239 days. This was 
based on most companies that operate on a five day work week, within the stipulated 
legal standard of 44 hours per week. This was deducted by 11 days of public holidays as 
well as the employee’s annual leave. Annual leave usually ranges from 7-14 days, and we 
used an average of 10 days in our model [125].  
Based on the NHSS 2007, the average number of cigarettes smoked a day is 13, 
throughout 16 hours of the smoker’s waking hours [6]. Hence, we assumed that a 
smoking employee would have smoked 6 cigarettes during his working hours. Consistent 
with published literature, we observed that an average cigarette break among office 
workers in the central business district took about 5 minutes, including the time taken to 
take the elevator and walk to the designated smoking area. Hence, the total length of 
smoking break per day assuming that 6 cigarettes were smoked during the work hours 
was estimated at 30 minutes [106]. Multiplying this by 239 days of working days per year, 
the amount of productivity time lost due to smoking breaks was 119.5 hours per year.  
2. Productivity loss due to increased absenteeism 
Published studies have reported that absence from work is higher among smokers 
compared to non-smokers, with one study estimating that difference as 4 days [106]. 
According to Singapore’s Ministry of Manpower data, an average employee works 8.24 
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hours a day (factoring in one hour lunch break) [125]. Hence, we estimated time lost due 
to absenteeism to be 32.96 hours per year.  
3. Total annual productivity loss 
Overall, total hours of lost productivity were estimated at 152.46 hours (119.5 hours + 
32.96 hours). In 2011, the median gross monthly wage of an employee was S$3249 
(US$ PPP 3008) and the average hours worked per week was 46.2 hours [125]. Hence, 
the estimated hourly wage was S$17.58 (US$ PPP 16.28), which then gives an annual 
productivity lost of S$2680 (US$ PPP 2481) (152.46 hours × S$17.58) per employee due 
to smoking.  
Sensitivity analyses 
Univariate sensitivity analyses were performed on key parameters and critical 
variables were presented as tornado diagram.  
1. Quit rates 
According to the USPHS guidelines, counseling results in a quit rate of 10.2% with a 95% 
confidence interval of 8.5% to 12%. Quit rates higher than 10.2% have been reported. In 
a meta-analysis of 20 controlled studies of work site smoking cessation, the weighted 
average follow-up quite rate from all interventions was 13% [126]. Although dated, this 
study is the most relevant to our setting. It has also been suggested that a quit rate of 20% 
is considered benchmark for clinic-based interventions [127]. Hence, we varied quit rates 
from 8.5% to 20%.  
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Ranges for the quit rates of NRT, bupropion and varenicline were computed following 
their respective 95% confidence intervals. The reported range of relative risk for NRT 
was 1.5 to 1.66 [67], bupropion was 1.53 to 1.85 [68] and varenicline was 1.95 to 2.8 [69]. 
Computed quit rates for the smoking cessation aids are shown in Table 5-1.  
2. Cost estimates 
We varied counseling cost from S$0 when they are offered as a free service by certain 
providers such as retail pharmacies to S$137 (US$ PPP 127) per employee when 
counseling is offered as group sessions. The cost estimates for the smoking cessation aids 
were varied by ±25% from the average unit price as provided by IMS Health data. We 
also conducted a random check of the retail prices of smoking cessation aids in 
pharmacies in Singapore to ensure that the prices fall within the ±25% range. Doses for 
NRT were also varied with the minimum and maximum recommended dosing for gums, 
lozenges and inhalers as needed. When doses were varied, the drug cost used in base case 
was applied. We assumed market share data to be accurate and did not conduct any 
sensitive analyses around it.   
3. Cost savings estimates 
Smoking break length ranges from 4-30 minutes per working day and the rate of 
absenteeism in employees who smoke versus non-smoker was varied from 0.7 to 7.3 
based on the study by Javitz et al [106]. Number of working days was varied from 235 
days (with 14 days of annual leave) to 294 days (assuming the employee works at the 
maximum 6 working days a week, and have only 7 days of annual leave). Hours worked 
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per day were varied from 8 hours till a maximum of 12 hours a day as stipulated by the 
Ministry of Manpower.  The employee’s hourly wage was also subjected to sensitivity 
analysis with a range of S$5.52 to S$35.88 (US$ PPP 5.11 to 33.22) according to the 
minimum and maximum wages shown in the Singapore Yearbook of Manpower 











Quit rates    
Counseling alone 10.2% 8.5% 20.0% 
Counseling + NRT 16.1% 15.3% 16.9% 
Counseling + bupropion 17.2% 15.6% 18.9% 
Counseling + varenicline 23.8% 19.9% 28.6% 
Cost estimates    
Counseling cost per employee S$48  S$0 S$137 
Cost of NRT  S$617 S$312 S$1491 
Cost of bupropion  S$363 S$272 S$454 
Cost of varenicline  S$660 S$495 S$825 
Cost savings estimates    
Productivity lost due to smoking 
breaks:  
   
     Number of working days per 
year 
239 235 294 
     Total length of smoking break 
per day (minutes) 
30 4 30 
Productivity lost due to 
absenteeism:  
   
     Extra number of days absent 
from work per year per smoking 
employee 
4 0.7 7.3 
     Hours worked per day (hours) 8.24 8 12 
Hourly wage per employee S$17.58 S$5.52 S$35.88 
 
In addition to sensitivity analyses on individual parameters, several alternative 
scenarios were constructed to account for various assumptions and objectives. To 
evaluate the costs and benefits for the company over a longer term, we conducted 
alternative scenario #1, where the program was implemented in the first year but the 
program effectiveness evaluated over two years. We made the assumption that for the 
same cohort of employees who smoked, no additional cost would be incurred from the 
second year onwards while the company continued to enjoy cost savings due to sustained 
productivity gained over two years. The probability of having a relapse after successfully 
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quitting smoking and turnover as a result of people leaving the company were accounted 
for. Costs for the second year were discounted using the Singapore Government 1-year 
Book-Entry Treasury Bills of 0.29% per annum in 2012 [128]. 
In alternative scenario #2, the impact of co-payment by employees on the cost-
benefit of WPSCP was evaluated. In our base-case analysis, we assumed that all costs 
were borne solely by the company. However, in the “real-world” setting, it is more likely 
that the company would be more open to a co-payment scheme with the employee who 
wishes to quit smoking. We evaluated various levels of co-payment (10%, 30% and 50% 
co-paid by the company). Recognizing that take-up rate by employees will depend on the 
amount of co-payment (with higher participation expected for higher company co-
payment), we varied the take-up rate for various levels of co-payment. We arbitrarily 
assumed that take up rate will drop by 1% for every 1% increase in co-payment by 
employee.     
 
5.3 Results 
In base-case analysis, the one-year cost to the company ranged from S$70 
(US$ PPP 65) per employee on counseling and varenicline to S$233 (US$ PPP 216) per 
employee on counseling and NRT. However, the program will be cost-beneficial to the 
company if the employee is on counseling and bupropion (savings of S$50 (US$ PPP 46) 
per employee) or if the employee is on counseling alone (S$225 (US$ PPP 208) per 




Figure 5-2 Net benefit to companies in the base-case analysis of the four smoking 
cessation regimens 
A positive value indicates a saving to the company, whereas a negative value indicates a 
cost incurred by the company 
 
Assuming that 100 smoking employees were enrolled with equal take-up rate 
across the four smoking cessation regimens (i.e. 25 smokers in each regimen), the 
weighted average cost of the program in the first year would be S$700 (US$ PPP 648). 






Table 5-2 Weighted average cost or benefit for a hypothetical company of 100 smoking 
employees in the first year of implementation of workplace smoking cessation program 
Treatment 




Total net benefit 
Counseling alone  S$225 S$5625 
Counseling + NRT  -S$233 -S$5825 
Counseling + bupropion  S$50 S$1250 
Counseling + varenicline  -S$70 -S$1750 




A positive net benefit value indicates a saving to the company, whereas a negative value 
indicates a cost incurred by the company                                                                                           
NRT nicotine replacement therapy 
 
Sensitivity analyses  
As indicated by the Tornado diagram, the three parameters with the most 
uncertainty were hourly wage of employees, quit rate of counseling and smoking break 




Figure 5-3 Tornado diagram 
 Q quit rate, NRT nicotine replacement therapy, EV expected value 
 
 
The results were robust (i.e. remained cost saving) with respect to most quit rates, 
costs and savings estimates except for hourly wage of employees. Program cost was 
sensitive to variations within the stated range of hourly wage of employees (Figure 5-4). 
At an hourly wage of S$31.83 (which is towards the higher end of the range), varenicline 





Figure 5-4 Sensitivity analysis on hourly wage of employees 
NRT nicotine replacement therapy 
 
Alternative scenario #1 – Effectiveness of WPSCP evaluated over two years 
From the second year onwards, no cost would be incurred for the same 100 
smoking employees, but the company would continue to enjoy savings due to avoided 
productivity lost, which was estimated at S$2680 (US$ PPP 2481) per year per employee. 
Assuming a relapse rate of 8% [129] and turnover rate of 20%, the company can enjoy a 
savings of S$32068 (US$ PPP 29693) in the second year. Details are provided in Table 
5-3. Nett savings after taking the first year program cost of S$700 (US$ PPP 648) into 
account was S$31368 (US$ PPP 29044).  
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Table 5-3 Total savings for a hypothetical company of 100 smoking employees in the 
second year of implementation of workplace smoking cessation program 
Treatment Number of 
employees who 
remained smoke 
free in the 
second year† 
Savings  = S$2680 




Counseling alone 2 S$5360 S$5345 
Counseling + NRT 3 S$8040 S$8017 
Counseling + bupropion  3 S$8040 S$8017 
Counseling + varenicline  4 S$10720 S$10689 
Total annual savings to the company in the second year of 
implementation  
S$32068 
Nett savings to the company (2 years after implementation of 
WPSCP, less the first year program cost of S$700) 
S$31368 
†
 Calculated using the formula [25×Quit rate×(1- relapse rate)×(1-turnover rate)], where 
relapse rate was assumed to be 8% and turnover rate was 20% 
‡ 
Discount rate was based on the Singapore Government 1-year Book-Entry Treasury 
Bills of 0.29% per annum in 2012 
NRT nicotine replacement therapy, WPSCP workplace-based smoking cessation program 
 
Alternative scenario #2 - Co-payment  
Table 5-4 shows the effect of varying co-payment rate on the cost-benefits of the 
program. Where necessary, the numbers were rounded up. For example, at 90% co-
payment by smoking employee, we assumed that 12 employees (3 in each of the four 
smoking cessation regimen) would enroll in the program. 
Supposing that employee and company co-pays 50% each, then the cost saving 
can be achieved even in the first year.  Instead of costing the company S$700 (US$ PPP 
648) per year (base-case), a savings of S$10669 (US$ PPP 9879) to the company can be 
achieved at the end of the first year. The savings would be smaller at S$4665 (US$ PPP 
4319) if co-payment by the employee increases to 90% as the take up rate by employees 
was assumed to fall to 10%.  
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Table 5-4 Effects of varying percentages of co-payment amongst companies and 
smoking employees on savings to company in the first year 









Company              
co-pays 
10%; 
Employee               
co-pays 
90% 
Company               
co-pays 30%; 
Employee              
co-pays 70% 
Company                 
co-pays 
50%; 
Employee             
co-pays 
50% 
Take-up rate                              
(Number of employees) 
100 12 32 52 
Counseling alone S$225 S$259 S$249 S$240 
Counseling + NRT  -S$233 S$349 S$216 S$83 
Counseling + bupropion  S$50 S$403 S$321 S$239 
Counseling + varenicline  -S$70 S$544 S$402 S$261 
Nett benefit of program to 
company 
-S$700 S$4665 S$9504 S$10699 
†
A positive net benefit value indicates a saving to the company, whereas a negative value 
indicates a cost incurred by the company 
NRT nicotine replacement therapy 
 
5.4 Discussion 
Our results showed that although it costs the company S$700 (US$ PPP 648) to 
carry out WPSCP in the first year, the program can potentially generate savings to the 
company if it is continuously carried out for more than a year or if co-payment is 
introduced. The cost savings two years after implementation of WPSCP was estimated at 
S$31368 (US$ PPP 29044) if the discount rate is set as the government bond rate. The 
cost savings is marginally lower at S$29840 (US$ PPP 27630) if the conventional 
discount rate of 5% is used [130]. Studies done by other groups have similarly showed 
that offering smoking cessation in the workplace can be cost-beneficial. Javitz et al 
evaluated the return on investment and internal rate of return of two dosing schedules of 
bupropion in combination with counseling of minimal or moderate intensity. The study 
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suggested that employers can receive competitive returns by sponsoring smoking 
cessation [105]. Although some companies may be skeptical and think that the benefits 
will be reaped by the individual or community rather than the companies themselves, 
Warner et al showed that even when half the benefits of smoking cessation was realized 
by the community, smoking cessation remained a very sound economic investment for 
the firm, and is particularly profitable when long-term benefits were included, with an 
eventual benefit-cost ratio of 8.75 [131]. In that study, the authors used a simulation 
model to examine the health and economic implications of a WPSCP that included 
consideration of long-term as well as short-term implications and evaluation of the effects 
of employee turnover on benefits derived by both the firm and the broader community. 
The results of our study may encourage employers to implement WPSCP within the local 
community. It may also serve as guidance for government agencies to conduct budget 
impact analyses and to decide whether more financial incentives should be provided to 
companies for implementation of WPSCP. 
In our study, amongst the four smoking cessation regimens, the most cost-
beneficial to the company appeared to be counseling alone (savings of S$225 (US$ PPP 
208)), whereas counseling plus NRT appeared to be most costly (cost of S$233 (US$ PPP 
216)). Counseling plus bupropion was also able to generate a savings of S$50 (US$ PPP 
46) whereas counseling plus varenicline cost the company S$70 (US$ PPP 65). Decision 
tree analyses were similarly carried out by other studies. Nielsen and Fiore showed that 
bupropion is more cost-beneficial than either nicotine transdermal patch (NTP) or a 
combination of bupropion/ NTP [132], while Jackson et al concluded that varenicline’s 
economic benefit is improved over bupropion [133]. However, to the best of our 
107 
 
knowledge, our paper was the first to compare the cost-benefit of all first line smoking 
cessation pharmacotherapies. Although our decision tree was imputed with local 
Singapore data, the structure of the model can be easily adapted by other countries and 
populated with their local data.  
We acknowledged several limitations with this study. First, we only discussed the 
costs and benefits from the companies’ perspective in the short term and did not attempt 
to value it from a societal perspective. This is because we have limited data on the 
turnover rate of employees in a company and morbidity and mortality costs due to 
smoking. The last published study on the societal costs of smoking in Singapore was 
conducted more than a decade ago [35]. However, we may expect that if a societal 
perspective was adopted, the cost-benefits would be even greater, as the morbidity and 
mortality costs due to smoking are known to be large. Second, other published studies 
included savings such as reduced property damage due to smoking related fires or 
avoidance of second hand smoke but these were not included in our model due to the 
nation-wide ban of indoor smoking in Singapore. However, if these savings were 
included, they should add to the cost-benefit of the program. Third, excess insurance cost 
due to smoking was not included as we were informed that insurance premiums paid by 
employers and insurance benefits received by employees do not differ by smoking status. 
Fourth, adverse drug events associated with the use of smoking cessation aids were not 
included because these were assumed to be self-limiting. Fifth, based on the current 
situation in Singapore, all smoking cessation programs are conducted outside of the 
working hours. If this situation changes, or if this is not the norm in other countries, then 
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the cost to employers of conducting smoking cessation programs during work hours 
would need to be incorporated.  
5.5 Conclusion 
Our study showed that the most cost-beneficial smoking cessation treatment was 
counseling alone (savings of S$225 (US$ PPP 208)), whereas counseling plus NRT 
appeared to be most costly (cost of S$233 (US$ PPP 216)). Counseling plus bupropion 
was also able to generate a savings of S$50 (US$ PPP 46) whereas counseling plus 
varenicline cost the company S$70 (US$ PPP 65). In the first year of implementation, the 
cost to carry out WPSCP in a hypothetical company of 100 smoking employees was 
S$700 (US$ PPP 648). However, the program can be potentially cost saving to the 
company if it is continuously carried out for more than a year or if co-payment by 
employee is introduced.  
 
5.6 Acknowledgments 
Dr Wee Hwee Lin was a consultant to and received funding (under an Investigator 
Initiated Research Grant) from Pfizer Pte Ltd. The funders had no role in study design, 
data collection and analysis, decision to publish, or preparation of the manuscript. In 
addition, we acknowledge the in-kind contributions of IMS Health Incorporated, 
Singapore which provided market sales data and pricing information of nicotine 
replacement gums, lozenges, patches and inhalers, as well as bupropion (Zyban™) and 
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In the last chapter of this thesis, we revisit the motivations for this thesis and 
summarize the findings and contributions which can be broadly divided into two sections. 
The first pertains to the humanistic burden of smoking in Singapore and the second 
pertains to ways in which uptake of WPSCP can be further enhanced in Singapore. The 
limitations of each chapter have been discussed in detail in the various chapters and will 
not be repeated here. Recommendations on future research will also be provided in the 
hopes of seeing more WPSCP offered in workplaces as one of the components in 
reducing overall smoking prevalence in Singapore.  
1. Burden of smoking in Singapore, focusing on the humanistic burden 
Through literature search, we found substantial information on the economic and 
clinical burden of smoking locally, but not on its humanistic outcome. Hence, in Chapter 
2 of the thesis, we investigated the association of smoking status with HRQoL in a 
multiethnic Singapore population. We found that smoking was associated with a trend of 
lower HRQoL, with female regular smokers reporting significantly lower HUI3 utility 
scores compared with never smokers. Male ex-smokers reported the lowest score on most 
scales, with significantly lower SF-36v2 MCS and HUI3 utility scores compared with 
never smokers. Such findings have also been reported in other countries such as the US 
[99] and Australia [38]. Furthermore, it has been suggested that the length of time since 
quitting smoking may affect HRQoL. Hence, future studies may want to capture 
information on time since quit smoking and its correlation with HRQoL. Further 
qualitative studies may also be warranted to understand the reasons for this observation 
and to better understand the needs of these individuals.  
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To the best of our knowledge, this is the first study to evaluate the effects of 
smoking on humanistic outcomes in Singapore and in an Asian general population. 
Hence, it has important implications to the design and delivery of public health smoking 
cessation initiatives. Besides emphasizing the adverse effects of smoking and lower 
HRQoL amongst smokers, strategies that seek to improve the HRQoL of ex-smokers may 
be warranted to prevent their relapse.  
2. Encouraging uptake of WPSCP in Singapore  
To address the problem of smoking and its burden, the workplace would be a 
good setting to promote smoking cessation. However, we found that WPSCP is not 
widely adopted locally. Hence, in Chapter 3 of this thesis, we identified barriers, benefits 
and resources needed in implementing WPSCP as perceived by 40 companies/ employers 
who participated in the face-to-face interviews. The top 3 barriers mentioned by 
respondents were perceived low participation rate, reluctance to interfere in employees’ 
smoking habits and fear of inciting negative emotions. Nevertheless, 62.5% of the 
respondents felt that they should take an interest in helping their employees to quit 
smoking. They mentioned benefits such as good for health, promote a healthy working 
environment, and also to improve employees’ productivity. They believed that 
management’s approval and support are crucial, as well as budget and manpower to 
implement the program. Half of the respondents mentioned that they plan to implement 
WPSCP within the next 12 months. 
With this study, we have a better understanding of employers’ motivations and 
challenges in implementing WPSCP in Singapore, which would be useful for public 
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health policy makers in devising appropriate smoking cessation programs. Identifying the 
barriers would contribute to the formulation of appropriate strategies to overcome them 
and produce better outcomes in any smoking cessation programs. Highlighting the 
benefits can raise the public’s awareness of WPSCP and its potential as a smoking 
cessation avenue. Lastly, by identifying the resources needed, appropriate support can be 
rendered thus making the implementation of WPSCP more of a reality.  
Chapter 4 was further developed to show the smoking cessation interventions that 
can possibly be implemented, based on the perceived effectiveness, feasibility and 
willingness of employers to implement them within their workplaces. The results 
suggested that smoking cessation posters and talks were the most likely to be 
implemented in WPSCP. On the other hand, prescription medication and off-site group 
counseling which were not favored by employers despite evidence-based effectiveness 
should be given more attention and better promotion. We have also found that there 
appeared to be a difference in willingness to implement smoking cessation interventions 
between company sizes and types, the results which could be validated in future studies 
with different sectors of companies.  
The results from this chapter provided interesting and useful information to public 
health policy makers in devising WPSCP with appropriate interventions that are 
acceptable and implementable within the workplace. It is clear from our findings in 
Chapters 3 and 4 that the government has a large role to play in terms of promoting 
uptake of smoking cessation programs.  
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Lastly, chapter 5 showed that the most cost-beneficial smoking cessation 
treatment was counseling alone (savings of S$225 (US$ PPP 208)), followed by 
counseling plus bupropion (savings of S$50 (US$ PPP 46)). Counseling plus NRT 
appeared to be most costly (cost of S$233 (US$ PPP 216)) and counseling plus 
varenicline cost the company S$70 (US$ PPP 65). Although it cost the company S$700 
(US$ PPP 648) to carry out WPSCP in the first year (in a hypothetical company with 100 
smoking employees), the program can potentially generate savings to the company if it is 
continuously carried out for more than a year or if co-payment is introduced.  
These findings showed that there is a business case in providing WPSCP in 
Singapore and may encourage employers to implement it within the local community. 
Additionally, we have provided a model to evaluate the cost-benefit of providing WPSCP, 
which could be adapted by other countries with their local data. It may also serve as 
guidance for government agencies to conduct budget impact analyses and to decide 
whether more financial incentives should be provided to companies for implementation 
of WPSCP.  
Due to the limited time, we were unable to embark on evaluating certain aspects 
of WPSCP, which we think are pertinent and warrants further study: 
 Further research could be carried out on different approaches to increase uptake 
rate of WPSCP by employers. For example, innovative ways to engage employers 
such as providing tax relief to the company upon providing subsidy for smoking 
cessation aids such as NRT or those that provide behavioral counseling.  
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 A further extension of the study on the perceived barriers, benefits and resource 
needs, as well as smoking cessation interventions implementable would be to 
gather input from the employees’ perspective (on top of the employers’), 
especially those who are smoking. Understanding the resources needed by the 
smokers themselves and types of program suitable for them would aid in the 
design of an acceptable program and hence increase their participation rate in 
WPSCP.  
 We have also not assessed characteristics of companies that would offer WPSCP 
as well as factors in the workplace that promotes smoking cessation. This is an 
important factor to ensure that smoking cessation efforts are sustainable in the 
workplace.  
 Industry specific initiatives may be more cost-effective than generic WPSCP.  
 Finally, as the profile of smokers is increasingly younger, there may be a need to 
explore the cost-effectiveness of workplace-based programs targeted at younger 
smokers or even the cost-effectiveness of school-based smoking cessation 
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Appendix I Ten Key Guideline Recommendations on Treating 
Tobacco Use and Dependence 
Source: The United States Public Health Services Clinical Practice Guideline: Treating 
Tobacco Use and Dependence: 2008 Update 
1. Tobacco dependence is a chronic disease that often requires repeated intervention 
and multiple attempts to quit. However, effective treatments exist that can 
significantly increase rates of long-term abstinence. 
2. It is essential that clinicians and healthcare delivery systems consistently identify 
and document tobacco use status and treat every tobacco user seen in a healthcare 
setting.  
3.  Tobacco dependence treatments are effective across a broad range of populations. 
Clinicians should encourage every patient willing to make a quit attempt to use 
the counseling treatments and medications recommended in this guideline.  
4. Brief tobacco dependence treatment is effective. Clinicians should offer every 
patient who uses tobacco at least the brief treatments shown to be effective in this 
guideline. 
5. Individual, group and telephone counseling are effective and their effectiveness 
increases with treatment intensity.  Two components of counseling are especially 
effective and clinicians should use these when counseling patients making a quit 
attempt - Practical counseling (problem-solving/skills training) and social support 
delivered as part of treatment.  
127 
 
6. There are numerous effective medications for tobacco dependence and clinicians 
should encourage their use by all patients attempting to quit smoking, except 
when medically contraindicated or with specific populations for which there is 
insufficient evidence of effectiveness (i.e., pregnant women, smokeless tobacco 
users, light smokers and adolescents).  Seven first-line medications (5 nicotine 
and 2 non-nicotine) reliably increase long-term smoking abstinence rates. 
Clinicians should also consider the use of certain combinations of medications 
identified as effective  in this guideline. 
 Nicotine gum 
 Nicotine lozenge 
 Nicotine patch 
 Nicotine nasal spray 
 Nicotine inhaler 
 
 Bupropion SR 
 Varenicline 
7. Counseling and medication are effective when used by themselves for treating 
tobacco dependence. However, the combination of counseling and medication is 
more effective than either alone. Thus, clinicians should encourage all individuals 
making a quit attempt to use both counseling and medication.  
8. Telephone quitline counseling is effective with diverse populations and has broad 
reach. Therefore, clinicians and healthcare delivery systems should both ensure 
patient access to quitlines and promote quitline use.  
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9. If a tobacco user is currently unwilling to make a quit attempt, clinicians should 
use the motivational treatments shown in this guideline to be effective in 
increasing future quit attempts.  
10. Tobacco dependence treatments are both clinically effective and highly cost-
effective relative to interventions for other clinical disorders. Providing coverage 
for these treatments increases quit rates. Insurers and purchasers should ensure 
that all insurance plans include the counseling and medication identified as 
effective in this Guideline as covered benefits.  
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 Banking/ Finance/ Insurance services                    1  
 Community, social and personal services              2  
 Information & communication services 
 
3  
 Retail trade 4  
 
Good morning / afternoon / evening. My name is ________________________ and I am calling on 
behalf of Nielsen. We are conducting a research survey on behalf of the Department of Pharmacy, 
National University of Singapore. We would be grateful if you could spare us a few minutes of your 
time. Please be assured we are not trying to sell you anything and that the information we are 
seeking is not of a sensitive / personal nature.  
 
Q2 ASK ALL 
Does your company currently have a Smoking Cessation 
Programme (i.e. a formal programme involving professionals to 






 Yes 1 CLOSE 
 No  2  
 
Q3 ASK ALL 
May I know how many employees are currently employed by your 





 Less than 100 staff 1 CLOSE 






Q4 ASK ALL 





 General Management (CEO, Managing Director, Executive 
Director) 
01 CLOSE 
 Administrative/Secretarial 02 CLOSE 
 Human Resource Management/ Development/Compensation & 
Benefits 
03  
 Finance and Accounting 04 CLOSE 
 Operations/ Logistics/ Procurement 05 CLOSE 
 Sales & Marketing/ Advertising & Promotion 06 CLOSE 
 Engineering 07 CLOSE 
 Legal Services 08 CLOSE 
 IT Services 09 CLOSE 
 Communications/ Public Relations 10 CLOSE 
 Research & Development 11 CLOSE 
 Others, please specify 12 CLOSE 
 
NOTE TO INTERVIEWER: IF RESPONDENT IS NOT AN HR MANAGER/PERSON 
(NOT CODED 3 IN Q4), ASK HIS CONSENT TO FORWARD YOU TO THE COMPANY'S 
HUMAN RESOURCE MANAGER/PERSON. IF HR PERSON IS NOT AVAILABLE, ASK 
FOR THE CONTACT DETAILS AND THANK RESPONDENT. 
 
Q5 ASK ALL 





 Senior Management (e.g. Branch Manager, Division Head, 
Director, Senior Manager) 
2  
 Middle Management (e.g. Department Heads, Managers) 3  
 Supervisors/ Executives/ Senior Officers 4  




Q6 ASK ALL 
Which of the following statement best describes you?  
 
NOTE TO INTERVIEWER: 
Definition of employee health related issues = Identification of 
health condition or non-work related injuries impacting the 
employee's ability to carry out the inherent requirements of his 
position. For example, managing of medical issues among 









 I am the person mostly responsible for employee health related 
matters 
1  




 I am involved in most employee health related matters/issues 3  





INVITATION TO TARGET RESPONDENTS 
For this study, we would like to invite you to participate in a one-to-one interview, where we can 
discuss your company's smoking policies. You do not have to answer any questions that you are 
uncomfortable with. Please be rest assured that all the data provided will be used strictly for 
research purposes and will be confidential.  The whole interview will last about forty minutes. The 
interview may be carried out at a place and time convenient to you.  
 




Q7 ASK ALL 





 Yes [PROCEED TO CONFIRM SCHEDULE AND VENUE] 
 
1  





Q8 INTERVIEWER TO RECORD 
Please provide the following details 
  
  
(R1)  RESPONDENT NAME 
 
Q9 INTERVIEWER TO RECORD 
Please provide the following details 
  
(R1)  CONTACT NO (MOBILE 
PREFERRED) 
        (140-147) 
(R2)  DDMMYY (INTERVIEW 
SCHEDULE) 
        (148-155) 
(R3)  TIME OF INTERVIEW (24 HOUR 
FORMAT) 
        (156-163) 
 
 
INTRODUCTION (BEFORE START OF THE MAIN INTERVIEW) 
Good morning / afternoon / evening. First of all, I would like to thank you for your participation on 
this study. 
 
My name is ___________ and I am currently working on a project on workplace-based smoking 
cessation programme. We are conducting this research on behalf of the Department of Pharmacy, 
National University of Singapore 
 
Smoking is the largest cause of preventable death and ill health. The workplace setting is an ideal 
environment to encourage smokers to quit as employees spend almost two thirds of their waking 
hours at work. With the reduction in smoking prevalence and thus the excess morbidity and 
mortality associated with smoking, employers that provide cessation support could benefit from 
reduced sickness absence and increased productivity. 
 
This interview is divided into three parts. In the first part, we would like to have an understanding 
about the current smoking policies in your company (if any) and your views about how you can 
further support your employees to quit smoking. In the second part, we would like to know the 
potential cost savings to your company if a workplace-based smoking cessation programme is 
carried out within your company. In the last part, we would like to obtain some of your company's 
background information. Please be assured that we are not here to sell you any services. We are 
researchers from Nielsen trying to understand the issues better so as to inform policy making.  
 
Before starting the discussion, please allow me to go over several points with you:  
1. The interview will last approximately forty minutes, but you may stop at any time during the 
interview if you no longer wish to continue.  
 
2. The interview is being recorded. However, it will be kept strictly confidential and it is solely 
intended for the researchers who are in charge of carrying out this survey. Due to the length of our 
discussion, it is necessary for us to record the discussion on digital voice recorder in order not to 
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miss out important points. With the digital recordings, we do not need to return to your company at 
a later date for any clarifications. Hence, this will be more convenient for your company as well. 
However, if you do not wish to be audio recorded, please feel free to say so and field notes will be 
taken instead. 
 
3. There are no right or wrong answers, and it is okay to say, “I don't know.” Please know that your 
name and your company's name will not be used in any reports and your company's participation is 
completely voluntary.   
 
Do you have any questions for us before we begin? [INTERVIEWER: Answer questions, if any]. If 











 Interview is audio recorded 1  





Q11 RECORD DATE 
  
(R1)  DD/MM/YY       (165-170) 
 
Q12 ASK ALL  
Please kindly state:  
  
  
(R1)  Designation 
                 (171-174) 
  
(R2)  Please give a brief description of your job scope 
                 (175-178) 
 
 
Q13 ASK ALL 










Q13 ASK ALL 





 Yes, partial restriction (Indoor smoking is prohibited but there are 
designated smoking areas outdoors) 
2 Q14 
 No 3 Q15 
 
Q14 ASK IF CURRENT COMPANY HAVE A NO SMOKING POLICY (Q13=1 OR 2) 
If yes, please briefly describe your company's current “no smoking policy”  
                 (180-216) 
 
 
Q15 ASK IF CURRENT COMPANY DO NOT HAVE NO SMOKING POLICY (Q13=3) 
If no, can we understand why so?  
                 (217-220) 
 
 
Part 1: Perceived barriers, benefits and resource use 
Let us discuss on perceived barriers, benefits and resources needed when implementing a 
workplace-based smoking cessation programme. 
  
 
Q16 ASK ALL 
What are the reasons why your company does not have a Smoking Cessation Programme?  
 
READ OUT: Smoking Cessation Programme is a formal programme involving 
professionals (like doctors, nurses or pharmacists) to help employee quit smoking 
  
                 (260-263) 
 
 
Q17 ASK ALL 
 
Are you aware of any smoking control resources offered in the 
community to help companies set up workplace-based smoking 
cessation programme? 
 
An example would be the smoking control resources offered to the 





 Yes 1  




Q18 ASK ALL 
Do you think that companies should take an interest in helping their 





 Yes 1 Q22 
 No 2 Q23 
 
Q19 ASK THOSE WHO THINK COMPANIES SHOULD TAKE AN INTEREST (Q21=1) 
If yes, why so?  
 
INTERVIEWER TO PROMPT: Company's social responsibility, Better image for the 
company, Increase productivity of its employees   
                 (266-269) 
 
 
Q20 ASK THOSE WHO DO NOT THINK COMPANIES SHOULD TAKE AN 
INTEREST (Q21=2) 
If no, could you please share with us why so? 
                 (270-273) 
 
 
Q21 ASK ALL 
What benefits, if any, do you see of promoting smoking cessation at the workplace? 
                 (274-277) 
 
 
Q22 ASK ALL 
What negative consequences, if any, do you see of promoting smoking cessation at the 
workplace? 
                 (278-314) 
 
 
Q23 ASK ALL 
What do you think employers could or should do to help their employees quit smoking, if 
any? 












I am going to read out/share a list of smoking control interventions (provided by doctors or 
pharmacists) that may be offered by your company.   
 
Q24 ASK ALL 
SHOWCARD: LIST OF INTERVENTIONS 
 
For each intervention, please state whether the method might be feasible in your company?  
 
NOTE TO INTERVIEWER:SINGLE RESPONSE PER ROW 
 Yes No Don't 
know/Not 
sure 
  (319)   
(R1)  Policies that ban smoking in the workplace 1 2 3 
  (320)   
(R2)  Having a contest or offering incentives to help workers 
quit 
1 2 3 
  (321)   
(R3)  Posters on smoking cessation or flyers promoting 
programs offered in the community, e.g. by HPB 
1 2 3 
  (322)   
(R4)  General information sessions, e.g. smoking cessation 
awareness talks offered by HPB 
1 2 3 
  (323)   
(R5)  Group smoking cessation counseling by professionals 
(e.g. doctors, nurses, pharmacists) offered on-site (in the 
company) 
1 2 3 
  (324)   
(R6)  Groups smoking cessation counseling by professionals, 
offered off-site 
1 2 3 
  (325)   
(R7)  One-on-one professional counseling  1 2 3 
  (326)   
(R8)  Over-the-counter medication - Nicotine replacement 
therapy - Gum, patch, lozenges, inhaler 
1 2 3 
  (327)   
(R9)  Prescription medication - Bupropion (Zyban®) or 
Varenicline (Champix®) 
1 2 3 
  (328)   




Q25 ASK ALL 
SHOWCARD OF SCALE 
Do you think the interventions will be effective if implemented in your company? Please 
score each item on a scale of 1 to 4 where 1 is “Not at all effective” and 4 is “Very 
effective”. 
NOTE TO INTERVIEWER:SINGLE RESPONSE PER ROW 











  (329)     
(R1)  Policies that ban smoking in the 
workplace 
1 2 3 4 5 
  (330)     
(R2)  Having a contest or offering 
incentives to help workers quit 
1 2 3 4 5 
  (331)     
(R3)  Posters on smoking cessation or 
flyers promoting programs offered 
in the community, e.g. by HPB 
1 2 3 4 5 
  (332)     
(R4)  General information sessions, e.g. 
smoking cessation awareness talks 
offered by HPB 
1 2 3 4 5 
  (333)     
(R5)  Group smoking cessation 
counseling by professionals (e.g. 
doctors, nurses, pharmacists) 
offered on-site (in the company) 
1 2 3 4 5 
  (334)     
(R6)  Groups smoking cessation 
counseling by professionals, 
offered off-site 
1 2 3 4 5 
  (335)     
(R7)  One-on-one professional 
counseling  
1 2 3 4 5 
  (336)     
(R8)  Over-the-counter medication - 
Nicotine replacement therapy - 
Gum, patch, lozenges, inhaler 
1 2 3 4 5 
  (337)     
(R9)  Prescription medication - 
Bupropion (Zyban®) or 
Varenicline (Champix®) 
1 2 3 4 5 
  (338)     




Q26 ASK ALL 
For each intervention, please state whether you are willing to implement them within your 
company?  
NOTE TO INTERVIEWER:SINGLE RESPONSE PER ROW 








  (339)   
(R1)  Policies that ban smoking in the workplace 1 2 3 
  (340)   
(R2)  Having a contest or offering incentives to help 
workers quit 
1 2 3 
  (341)   
(R3)  Posters on smoking cessation or flyers promoting 
programs offered in the community, e.g. by HPB 
1 2 3 
  (342)   
(R4)  General information sessions, e.g. smoking 
cessation awareness talks offered by HPB 
1 2 3 
  (343)   
(R5)  Group smoking cessation counseling by 
professionals (e.g. doctors, nurses, pharmacists) 
offered on-site (in the company) 
1 2 3 
  (344)   
(R6)  Groups smoking cessation counseling by 
professionals, offered off-site 
1 2 3 
  (345)   
(R7)  One-on-one professional counseling  1 2 3 
  (346)   
(R8)  Over-the-counter medication - Nicotine 
replacement therapy - Gum, patch, lozenges, 
inhaler 
1 2 3 
  (347)   
(R9)  Prescription medication - Bupropion (Zyban®) or 
Varenicline (Champix®) 
1 2 3 
  (348)   





Q27 ASK ALL 
What information is/are needed by your company/management in order to make a 
decision to implement a smoking cessation programme?  
 
 INTERVIEWER TO PROMPT: Who is going to make the final decision? What 
information do they need in order to implement the smoking control interventions?   
                 (349-352) 
 
 
Q28 ASK ALL 
What type of support or resources do you think are needed to implement the smoking 
cessation programme in your company?  
 
INTERVIEWER TO PROMPT:  Who needs to approve? Where does the money come 
from? 
                 (349-352) 
 
 
Q29 ASK ALL 
What barriers or challenges, if any, do you see of implementing the smoking cessation 
programme in your company?  
 
INTERVIEWER TO PROMPT: Lack of manpower, money to support the programme, 
support from the smokers themselves 
                 (353-356) 
 
 
Q30 ASK ALL 
What demonstrable/ measurable benefits have to be shown for continuation of the 
programme? 
                 (357-360) 
 
 
Q31 ASK ALL 
Will you consider a smoking cessation programme within your 





 Yes 1 Q35 
 No 2 Q34 
 
Q32 ASK THOSE WHO WILL NOT CONSIDER TO HAVE A SMOKING CESSATION 
(Q33=2) 
Why do you think your company will not consider to have a smoking cessation program in 





Part 2. Cost Savings 
 
The following section is regarding the cost savings to your company if a smoking cessation 
programme is carried out: 
 
Q33 ASK ALL  




 For executives - Less than SGD 2000                               
 
01 
 SGD 2000 - 3000                    02  
 SGD 3001 - 4000          03  
 SGD 4001 - 5000                   04  
 SGD 5001 - 6000                     05  
 More than SGD 6000 06  
 For non-executives - Less than SGD 1000                              
 
07  
 SGD 1000 - 2000                    08  
 SGD 2001 - 3000          09  
 SGD 3001 - 4000                   10  
 SGD 4001 - 5000                     11  
 More than SGD 5000 12  
 
Q34 ASK ALL 
How many hours do your employees work per day?  
(R1)  Executive (e.g. executive level & above)  
 
 (515-516) 
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 
  (517-518) 
 
Q35 ASK ALL 
How many days per week?  
(R1)  Executive (e.g. executive level & above)  
 
  (519-521) 
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 
   (522-524) 
 
Q36 ASK ALL 
How many days of annual leaves are your employees entitled to?  
(R1)  Executive (e.g. executive level & above)  
 
 (525-526) 
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 




Q37a ASK ALL 
What is the average number of days of medical leave taken by the typical employee who 
smokes?  
Q37b NOTE TO INTERVIEWER: PLEASE CIRCLE IF DATA ARE ESTIMATED. [MA] 
  
 
   Q59a Q59b 
  Average number of 




  (529-530) (533) 
(R1)  Executive (e.g. executive level & above)  
 
_ _ 1 
  (531-532)  
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 
_ _ 2 
 
Q38a ASK ALL 
What is the average number of days of medical leave taken by the typical employee who 
does not smoke? 
Q38b NOTE TO INTERVIEWER: PLEASE CIRCLE IF DATA ARE ESTIMATED. [MA] 
  
 
   Q60a Q60b 
  Average number of 




  (534-535) (538) 
(R1)  Executive (e.g. executive level & above)  
 
_ _ 1 
  (536-537)  
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 
_ _ 2 
 
Q39 ASK ALL 





 Yes 1 Q63 




Q40 ASK THOSE WHO DO NOT HAVE A DESIGNATED SMOKING AREA (Q61=2) 
Can you estimate how many people are working within the vicinity of the smoking 
employee (and hence would be exposed to the cigarette smoke)?  
  
(R1)      (540-
542) 
 
Q41 ASK ALL 





 Yes 1 Q64 
 No 2 Q65 
 
Q42 ASK THOSE WHO MENTIONED THERE WERE ACCIDENT / DAMAGES 
(Q63=1) 
If yes, please estimate the cost of such damages or accidents per annum.  
  




Q43a ASK ALL 
How many cigarettes do the typical employee who smokes in your company smokes on 
average, daily, during his/her working hours (excluding lunch and tea breaks)?  
  
Q43b NOTE TO INTERVIEWER: PLEASE CIRCLE IF DATA ARE ESTIMATED. [MA] 
  
 
   Q65a Q65b 
  Average number of cigarettes  (H1) Estimated 
  (550-551) (552) 
(R1)  No of cigarettes _ _ 1 
 
Q44 ASK ALL 
What is the average length of each smoking break? (In minutes) 
  
(R1)     (553-
554) 
 
Q45a ASK ALL 
What is the average company paid insurance premium for an employee in your company 
who smokes?  
  





   Q67a Q67b 








  (555-556) (559) 
(R1)  Executive (e.g. executive level & above)  
 
_ _ 1 
  (557-558)  
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 
_ _ 2 
 
Q46a ASK ALL 
What is the average company paid insurance premium for an employee in your company 
who does not smoke? 
  
Q46b NOTE TO INTERVIEWER: PLEASE CIRCLE IF DATA ARE ESTIMATED. [MA] 
  
 
   Q68a Q68b 




  (560-561) (564) 
(R1)  Executive (e.g. executive level & above)  
 
_ _ 1 
  (562-563)  
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 
_ _ 2 
 
Q47 ASK ALL 
Has the average company paid insurance premium per 





 Yes 1 Q70 




Q48 ASK THOSE WHO HAVE INCREASED PREMIUM IN THE 
PAST YEAR (Q69=1) 






 Increased claims in the preceding year 1  
 Increased number of employees with risk factors 2  
 Others, please specify: _______________________________ 3  
 
Part 3. General Information 
  
 
Q49a ASK ALL 
What is the total number of employees in your company? 
 
 
READ OUT IF RESPONDENT DOES NOT HAVE THE INFORMATION 
If data is not available, please provide an estimate.  
  
Q49b NOTE TO INTERVIEWER: PLEASE CIRCLE IF DATA ARE ESTIMATED. [MA] 
  
 
   Q16a Q16b 




  (221-224) (233) 
(R1)  Executive (e.g. executive level & above)  
 
_ _ _ _ 1 
  (225-228)  
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 
_ _ _ _ 2 
  (229-232)  
(R3)  TOTAL _ _ _ _ 3 
 
Q50a ASK ALL 
How many of your employees smoke? What is the proportion of your employees who 
smoke? If data is not available, please provide your best estimate in %.  
 
Q50b NOTE TO INTERVIEWER: PLEASE CIRCLE IF DATA ARE ESTIMATED. [MA] 
  
 
   Q17a Q17a 
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  (234-237) (234-237) 
(R1)  Executive (e.g. executive level & above)  
 
_ _ _ _ _ _ _ _ 
  (238-241) (238-241) 
(R2)  Non-Executive (e.g. assistant, coordinator, officer, etc) 
 
_ _ _ _ _ _ _ _ 
  (242-245) (242-245) 
(R3)  TOTAL _ _ _ _ _ _ _ _ 
 
Q51a ASK ALL 
How many of the employees who are currently smoking has the intention to quit smoking? 
Please provide your best estimate in %.  
 
  
Q51b NOTE TO INTERVIEWER: PLEASE CIRCLE IF DATA ARE ESTIMATED. [MA] 
  
 
   Q18a Q18b 
  % of employees who 




  (247-250) (259) 
(R1)  Executive (e.g. executive level & above)  
 
_ _ _ _ 1 
  (251-254)  
(R2)  Non-Executive (e.g. assistant, coordinator, officer, 
etc) 
 
_ _ _ _ 2 
  (255-258)  
(R3)  TOTAL _ _ _ _ 3 
 
